CIPRIANI & WERNER

A PROFESSIONAL CORPORATION

ATTORNEYS AT LAW

500 Lee Street East, Suite 900 Charleston, WV 25301

> Phone: (304) 341-0500 Fax: (304) 341-0507

ICA EFiled: Apr 03 2023 04:59PM EDT Transaction ID 69721543 Visit us online at www.C-WLAW.com

April 3, 2023

The Honorable Daniel Greear, Chief Judge West Virginia Intermediate Court of Appeals WV Judicial Tower 4700 MacCorkle Ave, SE Charleston, WV 24304

> RE: <u>Kermit Coles (deceased) v. Century Aluminum of West Virginia, Inc.</u> Appeal No: No. 23-ICA-81 Claim No.: C6720710144-01 JCN No.: 2021006800

Dear Judge Greear:

T. JONATHAN COOK, ESQ.

tcook@c-wlaw.com

Enclosed please find the original of the "Brief on Behalf of Century Aluminum of West Virginia" in the above claim.

Thank you for your consideration of this matter.

Very truly yours,

T. Jonathan Cook, Esquire

TJC/mm

Enclosure

CC: Century Aluminum of West Virginia (via e-mail) John H. Skaggs, Esquire Davies Group, Kimberly Lantz (via e-mail)

BEFORE THE INTERMEDIATE COURT OF APPEALS OF WEST VIRGINIA Charleston, WV

WANDA COLES, DEPENDENT OF KERMIT COLES (Deceased),

Appellant,

v.

Intermediate Court No. 23-ICA-81

CENTURY ALUMINUM OF WEST VIRGINIA, INC.,

Appellee.

BRIEF ON BEHALF OF APPELLEE CENTURY ALUMINUM OF WEST VIRGINIA

T. Jonathan Cook, Esq. *WV Bar ID #9057* Cipriani & Werner, P.C. 500 Lee Street East, Suite 900 Charleston, WV 25301

TABLE OF CONTENTS

	OF THE CASE	
STATEMENT O	OF THE FACTS	
SUMMARY OF	ARGUMENT	
STATEMENT R	REGARDING ORAL ARGUMENT	
ARGUMENT		
CONCLUSION		

TABLE OF AUTHORITIES

I. STATEMENT OF CASE

This claim involves dependents benefits after Mr. Kermit Coles (Mr. Coles or deceased worker) passed away from metastatic bladder cancer. Mrs. Wanda Coles (Mrs. Coles or dependent), alleged the metastatic bladder cancer was caused by Mr. Coles's employment with Century Aluminum of West Virginia, Inc. (Century or employer). Mrs. Coles's claim was denied on September 22, 2020. **EX 1**. Mrs. Coles opted to protest the denial of her claim for dependents benefits. Following discovery, however, the evidentiary record did not support this allegation. After weighing the evidence, the Workers' Compensation Board of Review (BOR) issued an order dated February 2, 2023, and correctly found:

The fact that the employee worked in the aluminum plant is not alone sufficient to establish causation of his bladder cancer. Although the claimant does not have to establish that the conditions of the employee's employment were the exclusive or sole cause of the disease, she has not shown a direct casual connection between the employee's work and his development of bladder cancer. The claimant has not met her burden of proof. The order of September 22, 2020, is affirmed.

EX 2 at 7. The BOR made this finding after reviewing medical reports by Dr. Werntz and Dr. Lultschik. The former suggested working in an aluminum plant increased Mr. Coles's development of bladder cancer. The latter advised there was no relationship explaining medical literature does not support an increased chance of cancer for workers in aluminum plants in the Untied States like the facility whether Mr. Coles worked in this claim.

Mrs. Coles disagreed with the BOR and filed this appeal.

II. STATEMENT OF FACTS

By way of background, Mr. Coles's employment history noted he spent time working as a

millwright in the pot room. Mr. Coles retired on May 1, 2007, and he passed away from bladder Page 3 of 15 cancer on January 14, 2020. The dependent's case relies on Dr. Charles Werntz's medical report dated April 21, 2021. **EX 3.** Dr. Werntz concluded Mr. Coles's development of bladder cancer was "significantly contributed to by his working in an aluminum production facility, including the potroom." **Id. at 5.** Dr. Werntz went on to say his opinion was supported by medical literature. **Id.** He also stated the risk of developing bladder cancer was significantly increased by his work in an aluminum production facility over what his risk would have been from smoking alone. **Id.** He finally opined without the additional risk from the aluminum production facility, it would have been less likely for him to have developed bladder cancer. **Id.**

Treatment records from Mayo Clinic and CAMC Memorial Division were part of the record but failed to discuss a relationship between Mr. Cole's cancer and his work at Century. See **Claimant's Appendix.** A review called "Cancer Risks in Aluminum Reduction Plant Workers" in support of the protest. **Claimant's Appendix – CX 3.**

Jennifer Lultschik, MD, MPH, the Public Health/General Preventive Medicine Program Director and Occupational Medicine Assistant Professor of the Occupational and Environmental Health Sciences at West Virginia University prepared a record review regarding causation of Mr. Cole's bladder cancer and his employment at Century. **EX 4.** In her report dated November 21, 2022, Dr. Lultschik concluded:

> In their 2014 review, Gibbs and Labreche noted that the exposures of concern in the aluminum reduction industry are the coal tar pitch volatiles (CTPV) and polyaromatic hydrocarbons (P AH) produced in the potroom. These arise chiefly from the carbon electrodes used in the process. In 2010 the IARC classified 'occupational exposures during carbon electrode manufacture' as Class 2A (probably carcinogenic to humans). Measurement of benzo(a)pyrene is typically used as an index of total P AH exposure.

> Gibbs and Labreche noted that prebake potrooms have much lower exposures and risks than potrooms using the older Soderberg process. They also noted that soot and coal tar pitch have been associated with limited human evidence for bladder cancer risk. They report that while studies have shown significant increased risk

from exposure in Soderberg potrooms in Canada and Norway, no significant change in risk of bladder cancer was seen in the United States and France. They state, "There was no excess of bladder cancer deaths in workers ever employed in the potrooms or carbon plants in the US studies."

The documents provided to me for review do not include a detailed job description of Mr. Coles's work at Century, nor quantitation of hours of exposure to CTPV per day or week during his time of employment there. There is no information regarding whether Century used the 'prebake' process or the 'Soderberg' process. Gibbs and Labreche do note that studies in Soderberg potrooms from Canada and Norway showed a strong association of exposure with bladder cancer, but they also state that bladder cancer was" ... detected at **statistically nonsignificant levels in the United States** ...".

There is a strong association between tobacco smoking and bladder cancer. Freedman et al noted that the medical literature placed the population-attributable risk for tobacco smoking and bladder cancer at 50-65%, meaning that tobacco smoking accounts for 50-65% of bladder cancer cases in men. Their own study confirmed a population-attributable risk for smoking of 50%. Smoking is recognized as the single greatest risk factor for urothelial carcinoma of the bladder.

Welty et al examined persistence of elevated risk of bladder cancer after smoking cessation; they found that the hazard ratio (HR) for bladder cancer in those with a 37.5 or more pack-year history of smoking was 2.77 (95% CI 2.00-3.85), and those who were less than 14 years since quitting tobacco smoking at the time of bladder cancer diagnosis had a HR of2.52 (95% CI 1.79- 3.53).4 From the medical record, Mr. Coles had a 42-year smoking history (1965 through 2007) and was known to be a 'heavy smoker'. A conservative estimate of 'heavy smoking' would be 1 pack per day; this would result in a 42 pack-year smoking history, with a hazard ratio of 2.77 as noted above. Welty also noted that an increased risk of urothelial carcinoma (UC) of the bladder persisted more than 32 years after quitting, and said, "This argues that a history of smoking should continue to be considered a strong risk factor for UC throughout a person's life."

Tobacco smoking accounts for 50-65% of cases of urothelial carcinoma of the bladder, and is single strongest risk factor for this cancer. While there is some evidence to support an association the between exposure to polyaromatic hydrocarbons (P AH) and CPTV in Soderberg potrooms Canada and Norway and bladder cancer, there have been no excess bladder cancer deaths in in US

studies. From the available information it is not possible to estimate the extent and duration of exposure sustained by Mr. Coles, or whether he worked in a Soderberg potroom. On the hand, Mr. Coles's 42+ pack-year tobacco smoking exposure places him at significantly other increased risk for urothelial carcinoma of the bladder, is a sufficient causative factor without any other exposure, and in my opinion is more likely than not the cause of his bladder cancer.

To answer your question, in my opinion it is more likely than not the claimant's bladder cancer was not caused by his employment at Century Aluminum.

The above opinions are given within a reasonable degree of medical certainty and within scope of my medical specialty, Occupational Medicine. . ..

EX 4 at 6-7.

Medical records from Mayo Clinic documented the claimant had malignant neoplasm of

the bladder lateral wall (ICD 10 - C67.2). EX 5. The records document the claimant smoking

one pack of cigarettes per day for 42 years. Id.

In affirming the denial of this claim, the BOR stated the following in its Order dated

February 2, 2023:

The claimant submitted the report of Dr. Werntz who concluded that the employee's development of bladder cancer was significantly contributed to by exposure while he was working at an aluminum production facility, including his work in the potroom. The employer submitted the report of Dr. Lultschik who noted that tobacco smoking accounts for 50% to 65% of cases of urothelial carcinoma of the bladder and is the single strongest risk factor for developing this type of cancer. The deceased employee smoked cigarettes for approximately 42 years.

The 2014 study by Gibbs and Labreche regarding the increased risk of bladder cancer in aluminum workers, was discussed by both Dr. Werntz and Dr. Lultschik. Dr. Lultschik relied on this report to support her conclusion that it is more likely than not that the employee's bladd r cancer was not caused by his employment at Century. In this regard, she noted that she did not have quantitation of the hours of exposure to CTPV per day or week during the employee's time

of employment and there was no information regarding whether Century used the prebake process or the older Soderberg process. Dr. Lultschik further indicated that Gibbs and Labreche noted that studies in Soderberg potrooms from Canada and Norway show a strong association of exposure with bladder cancer, but that bladder cancer was detected at statistically nonsignificant levels in the United States.

Dr. Lultschik provides more specifics about the 2014 study and the distinction in the risks for exposure to carcinogens between the "prebake" and the "Soderberg" processes. The evidence does not show which process was used by Century during the employee's time at Century, and there is no evidence regarding the extent of the employee's exposure to CTPV. Accordingly, Dr. Lultschik's report is more detailed and persuasive than the report by Dr. Werntz.

The fact that the employee worked in the aluminum plant is not alone sufficient to establish causation of his bladder cancer. Although the claimant does not have to establish that the conditions of the employee's employment were the exclusive or sole cause of the disease, she has not shown a direct causal connection between the employee's work and his development of bladder cancer. The claimant has not met her burden of proof. The order of September 22, 2020, is affirmed.

EX 2 at 7-8 (Emphasis added).

III. SUMMARY OF ARGUMENT

This appeal is simply an occupational disease claim involving the application of W. Va. Code § 23-4-1(f) which sets forth six elements to be eligible for benefits: "(1) that there is a direct causal connection between the conditions under which work is performed and the occupational disease, (2) that it can be seen to have followed as a natural incident of the work as a result of the exposure occasioned by the nature of the employment, (3) that it can be fairly traced to the employment as the proximate cause, (4) that it does not come from a hazard to which workmen would have been equally exposed outside of the employment, (5) that it is incidental to the character of the business and not independent of the relation of an employer and employee, and (6) that it must appear to have had its origin in the risk connected with the employment and to have flowed from that source as a natural consequence, though it need not have been foreseen or expected before its contraction." Pursuant to W. Va. Code 23-4-1g, the BOR must evaluate evidence and determine whether a claimant proved his or her claim by a preponderance of the evidence. When the BOR evaluates a claim, it utilizes a "process of weighing evidence [which] include[s], but [is] not be limited to, an assessment of the relevance, credibility, materiality and reliability that the evidence possesses in the context of the issue presented." <u>Wilkinson v. OIC & Putnam County Bd of Educ,</u> 222 W.Va. 394, 401, 664 S.E.2d 735, 742 (2008) (quoting 23-4-1g(a)). After weighing the evidence, the BOR found the Dependent fell short of establishing all six elements of an occupational disease and affirmed the denial of her claim. The BOR did not err by making that finding.

IV. STATEMENT REGARDING ORAL ARGUMENT AND DECISION

The facts and legal arguments are adequately presented by the Employer's brief and the record before the Court. Therefore, Century, by counsel, respectfully submits that oral argument is not needed for this appeal.

V. ARGUMENT

Standard of Review

The standard of review applicable to this Board's review of an OOJ's decision is set forth

under W. Va. Code § 23-5-12(b) which provides:

[The Board of Review] shall reverse, vacate, or modify the order or decision of the administrative law judge if the substantial rights of the petitioner or petitioners have been prejudiced because the administrative law judge's findings are: (1) In violation of statutory provisions; or (2) In excess of the statutory authority or jurisdiction of the administrative law judge; or (3) Made upon unlawful procedures; or (4) Affected by other error of law; or (5) Clearly wrong in view of the reliable, probative and substantial evidence on the whole record; or (6) Arbitrary or capricious or characterized by abuse of discretion or clearly unwarranted exercise of discretion.

W. Va. Code § 23-5-12(b).

A. The BOR correctly found the dependent did not prove by a preponderance of the evidence that Mr. Coles developed an occupational disease when the expert evidence showed it was more likely than not that his bladder cancer was either naturally occurring or related to his robust smoking history.

Mrs. Coles first assignment of error states the ". . . [BOR] erred in applying <u>Bradford v.</u> <u>Workers' Compensation Comm'r</u>, Syl. Pt 3, 185 W. Va. 434, 408 S.E.2d 13 (1991), which states that the claimant is only required to prove that an occupational injury or disease contributed in any material degree to the death and <u>Powell v. State Workmen's Compensation Commissioner</u>, 166 W. Va. 327, 273 S.E.2d 832 (1980) which holds that a claimant is not required to prove that an occupational exposure was the sole or exclusive cause of the disease." This assignment of error is framed to suggest an error of law rather what is nothing more than the dependent's disagreement over the manner in which the BOR weighed the evidence. Moreover, the dependent wants to revive the old rule of liberality rather than its replacement, W. Va. Code § 23-4-1g requiring proof by a preponderance of the evidence. <u>City of Wheeling v. Marriner</u>, No. 14–0498, (W. Va. Sup. Ct. 2015). The order shows the BOR did not commit reversible error in its Order.

First, the dependent characterizes her burden in the terms of an evidentiary standard eliminated by the Legislature with its enactment of W. Va. § 23-4-1g(b)("Except as provided in subsection (a) of this section, a claim for compensation filed pursuant to this chapter must be decided on its merit and not according to any principle that requires statutes governing workers' compensation to be liberally construed because they are remedial in nature. No such principle may be used in the application of law to the facts of a case arising out of this chapter or in determining the constitutionality of this chapter."). Here, the dependent's brief does not state but strongly suggests the West Virginia Supreme Court of Appeals decisions in <u>Bradford</u>, supra, and <u>Powell</u>, supra, do not require proof by a preponderance of the evidence. Rather the dependent believes evidence which merely implies the possibility of a relationship between some type of

exposure and a disease is sufficient to establish compensability. Such a characterization is inaccurate especially when looking at the basis of both decisions. Specifically, the <u>Powell</u> court stated:

And finally in <u>Myers v. State Workmen's Compensation Comm'r</u>, 160 W. Va. 766, 239 S.E.2d 124 (1977), we held that claimant's noise-induced gradual hearing loss was an occupational disease under the statute. In making this ruling we held it was not necessary for the claimant to prove that his hearing loss was not attributable completely to his age, and held that "it is not claimant's burden to negative all possible non-occupational causes of his injury. Id. at _____, 239 S.E.2nd at 127.

The <u>Myers</u> Court stated: "In applying the statute to the undisputed facts in this case, we begin with a fundamental rule of workmen's compensation law. A spirit of liberality is to be employed in applying the provisions of the Workmen's Compensation Act and in construing the evidence. This principle dictates that this Court examine the record and give the claimant the benefit of all reasonable inferences the record will admit favorable to him." 160 W. Va. at 770, 239 S.E.2d at 126. The <u>Powell</u> Court and <u>Bradford</u> Courts, which relied on <u>Myers</u>, also applied the rule of liberality in both decisions undermining both rulings on compensability. The option of applying the rule of liberality is no longer available. The finder-of-fact must apply W. Va. Code § 23-4-1g, which states:

(a) For all awards made on or after the effective date of the amendment and reenactment of this section during the year two thousand three, resolution of any issue raised in administering this chapter shall be based on a weighing of all evidence pertaining to the issue and a finding that a preponderance of the evidence supports the chosen manner of resolution. The process of weighing evidence shall include, but not be limited to, an assessment of the relevance, credibility, materiality and reliability that the evidence possesses in the context of the issue presented. Under no circumstances will an issue be resolved by allowing certain evidence to be dispositive simply because it is reliable and is most favorable to a party's interests or position. If, after weighing all of the evidence regarding an issue in which a claimant has an interest, there is a finding that an equal amount of evidentiary weight exists favoring conflicting

matters for resolution, the resolution that is most consistent with the claimant's position will be adopted.

Here, the finder-of-fact applied the preponderance of evidence standard to the record and concluded the most reasoned and supported opinion was offered by Dr. Lultschik whose report was supported by scientific studies showing cigarette smoking, a habit the deceased worker engaged in for 42 years, accounted for 50 to 65% of all cases of urothelial carcinoma of the bladder and was the "single strongest risk factor for developing this type of cancer." **EX 2 at 7-8**. Moreover, the finder-of-fact found medical literature which supported Dr. Lultschik that bladder cancer was "detected at statistically nonsignificant levels in the United States." The deceased worker worker at a facility in Ravenswood, WV. Thus, between the two possible risk factors, cigarette smoking overwhelmingly causes bladder cancer at a much higher rate than any other potential cause and bladder cancer is statistically nonsignificant for potroom workers in the United States. The BOR's finding:

The fact that the employee worked in the aluminum plant is not alone sufficient to establish causation of his bladder cancer. Although the claimant does not have to establish that the conditions of the employee's employment were the exclusive or sole cause of the disease, she has not shown a direct causal connection between the employee's work and his development of bladder cancer. The claimant has not met her burden of proof. The order of September 22, 2020, is affirmed.

is supported by substantial evidence. <u>See Board of Education of the County of Mercer v.</u> <u>Wert</u>, 192 W.Va. 568, 579, 453 S.E.2d 402, 413 (1994)("As a general rule, we uphold the factual findings of an ALJ if they are supported by substantial evidence.... We must defer to the ALJ's credibility determinations and inferences from the evidence, despite our perception of the other more reasonable conclusions from the evidence."). In sum, while the claimant may disagree with the assignment of weight to the evidence and hoped for a different outcome, a disagreement on the weight assigned to each piece of evidence is no sufficient to overturn the BOR's decision.

Second, the expert opinion relied upon by the dependent is weak. Dr. Werntz stated in his report that Mr. Coles's bladder cancer was "significantly contributed to by his working in an aluminum production facility, including the potroom." The evidence does not support Dr. Werntz. There was no information from the medical records (CAMC and Mayo Clinic) which suggested a relationship between Mr. Coles's bladder cancer and a workplace exposure. The study supporting Dr. Lultschik's report found incidents of bladder cancer connected to pot rooms in the United States were statistically "nonsignificant." Lastly, Mrs. Coles did not offer evidence of the type of process used at Century (prebake versus Soderberg). It is not Century's burden to establish no relationship exists between the bladder cancer and Mr. Coles's workplace. To the contrary, the dependent has the burden of establishing each and every element of an occupational disease and that the occupational disease caused Mr. Coles's death. Simply put, the dependent omitted that critical information here. The dependent's case has many holes regarding Mr. Coles's actual workplace exposure and the sufficiency of the same to the bladder cancer. Conversely, the record establishes the number one cause of bladder cancer is cigarette smoking and Mr. Coles's engaged in that habit for the majority of his life (one pack per day for 42 years). The BOR's order shows a command of the record and correctly affirmed the denial of the claim.

B. The BOR correctly found the dependent did not prove by a preponderance of the evidence that Mr. Coles had sufficient exposure to any hazard, other than tobacco smoke, to cause bladder cancer.

Mrs. Coles second assignment of error states the "The Board or Review erred in finding that the decedent's exposure was limited without the employer making any findings regarding exposure and was clearly wrong in light of the evidence offered by affidavit, social security earnings report, medical records, and expert report." In other words, the dependent wants this Court to impermissibly switch the burden to the employer to prove the elements of an occupational disease do not exist. This assignment of error violates W. Va. Code § 23-4-1g and is inconsistent with decisions of the West Virginia Supreme Court of Appeals which squarely place the burden of proof on the claimant to prove each and every element of an occupational injury or occupational disease. See e.g., Syl pt. 3, Deverick v. State Workmen's Compensation Director, 150 W. Va. 145, 144 S.E.2d 498 (1965) ("In order to establish compensability an employee who suffers a disability in the course of his employment must show by competent evidence that there was a causal connection between such disability and his employment").

In addition, each and every piece of evidence offered by the dependent was reviewed by Dr. Lultschik who was familiar with Mr. Coles's medical history, social history (42 pack/year smoker), and employment history. Dr. Lultschik decidedly concluded cigarette smoking, the overwhelming cause of bladder cancer, was the likely cause of Mr. Coles's cancer. Moreover, Dr. Lultschik cited scientific studies which showed workers performing similar jobs to the deceased worker in potrooms in the United States were not more likely than the general public to develop bladder cancer. This is a critical piece of evidence which Dr. Werntz was unable to overcome. Moreover, the dependent did not submit any evidence to refute this study or Dr. Lultschik's opinion on this issue.

The exposure issue was developed below, and the finder-of-fact concluded the evidence did not establish a causal connection between Mr. Coles's employment at Century Aluminum and his bladder cancer. Moreover, to the extent <u>Powell</u> states the following::

Unlike traumatic injuries, the causal connection for occupational diseases must be established by showing exposure at the workplace sufficient to cause the disease and that the disease actually resulted in the particular case. The standard for determining that connection is defined in W. Va. Code § 23-4-1, as whether the connection appears to the rational mind to meet the six factor test set out in the code. Whether a disease appears causally related to employment in the eyes of the rational mind will turn on the state of current

scientific knowledge. <u>Utter v. Asten-Hill Manufacturing</u> Co., 453 Pa. 401, 309 A.2d 583 (1973).

166 W.Va. at 336, 273 S.E.2d at 837, the scientific and medical evidence in this case establishes the dependent did not meet all each and every element of an occupational disease defined by W. Va. Code § 23-4-1(f) (1) That there is a direct causal connection between the conditions under which work is performed and the occupational disease; (2) that it can be seen to have followed as a natural incident of the work as a result of the exposure occasioned by the nature of the employment; (3) that it can be fairly traced to the employment as the proximate cause; (4) that it does not come from a hazard to which workmen would have been equally exposed outside of the employment; (5) that it is incidental to the character of the business and not independent of the relation of employer and employee; and (6) that it appears to have had its origin in a risk connected with the employment and to have flowed from that source as a natural consequence, though it need not have been foreseen or expected before its contraction...."

VI. CONCLUSION

The record establishes the number one cause of bladder cancer is cigarette smoking and Mr. Coles's engaged in that habit for the majority of his life (one pack per day for 42 years). The BOR did not commit reversible. Century, therefore, requests this Court to affirm the BOR's order dated February 2, 2023.

Respectfully submitted,

Century Aluminum of West Virginia By Counsel

T. Jonathan Esa. WV Bar-HD #9

Page 14 of 15

CERTIFICATE OF SERVICE

I, T. Jonathan Cook, Esq., attorney for the Appellant, Century Aluminum of West Virginia, certify that a true and exact copy of the foregoing "Brief on Behalf of Appellee, Century Aluminum of West Virginia" was served upon the Appellant by forwarding a true and exact copy thereof in the United States mail, postage prepaid, this 3rd day of April 2023 addressed as follows:

Mr. John H. Skaggs, Esquire Calwell Luce diTrapano PLLC Law and Arts Center West 500 Randolph Street Charleston, WV 25302

T. Jonathan Esq.

WV Bar-HD #9057

BEFORE THE INTERMEDIATE COURT OF APPEALS OF WEST VIRGINIA Charleston, WV

WANDA COLES, DEPENDENT OF KERMIT COLES (Deceased),

Appellant,

v.

Intermediate Court No. 23-ICA-81

CENTURY ALUMINUM OF WEST VIRGINIA, INC.,

Appellee.

APPENDIX OF EXHIBITS ON BEHALF OF APPELLEE CENTURY ALUMINUM OF WEST VIRGINIA

EXHIBITS

- Exhibit 1: Claim Administrator Order Denying Claim dated September 22, 2020
- Exhibit 2: Board of Review Decision dated February 2, 2023
- Exhibit 3: Medical Report of Dr. Charles Werntz dated April 21, 2021
- Exhibit 4: IME Report of Dr. Jennifer Lultschik dated November 21, 2022
- Exhibit 5: Select Medical Records from Mayo Clinic

CERTIFICATE OF SERVICE

I, T. Jonathan Cook, Esq., attorney for the Appellee, Century Aluminum of West Virginia , hereby certify that a true and exact copy of the foregoing appendix was served upon the Appellant by forwarding a true and exact copy thereof in the United States mail, postage prepaid, this 3rd day of April, 2023, addressed as follows:

> John H. Skaggs, Esquire Calwell Luce diTrapano PLLC Law and Arts Center West 500 Randolph Street Charleston, WV 25302

T. Jonathan Cook, Esq. WV Bar-HD #9057

Workers' Compensation Board of Review P.O. Box 2628 Charleston, WV 25329-2628 (304) 558-5230

Document Submission Form

Claimant: Kermit Cole (deceased)

Employer(s): Century Aluminum of West Virginia

JCN No: 2021006800

Carrier Ref. No.: C6720710144-01

DOI / DLE: 5/01/2007

Submitting Party: T. Jonathan Cook, Esq. Representing Employer

Reference: September 22, 2020

Short Description(s) of Order: Denied death benefits

Please Select One of the Following Categories: Attach only (1) document per form

Evidence: Claim Administrator order dated September 22, 2020

Date: September 29, 2022

Submitted by:

T. Jonathan Copk Esq.

WV Bar HD # 9057

TJC/mm

Enclosure

cc: John H. Skaggs, Esquire Davies, Doniela Fiato (via e-mail) Century Aluminum of West Virginia (via e-mail)





P.O. Box 291587 Nashville TN | 37229-1587 | USA

t: 800-322-1276 / 615-360-2800 mdjuster fax: 615-360-5698 claim support fax: 615-360-5689 metro fax: 615-360-5692 www.davles-group.com

September 22, 2020

Ms. Wanda Coles 1006 Dupont Ave Nitro, WV 25143

RE: Claim No.: C6720710144-01 DOI: 5/1/2007

We are the Third-Party Administrators handling claims for Century Aluminum. Your application for dependent benefits is denied as there is not sufficient medical evidence to establish a connection between the decedent's condition and his employment.

You may protest this decision within sixty (60) days from the date you receive this letter. You must send a written protest, along with a copy of this order, to the Office of Judges, P.O. Box 2233, Charleston, WV 25328-2233. Copies must also be sent to all other parties to the claim.

If you have any questions or concerns, you may contact me at 615-360-1388.

Very truly yours,

Stephanie Critcher

Stephanie Critcher

cc: Laura Tuisl <u>laura.tuisl@genturyaluminum.com</u> Christy Quataker <u>christy.quataker@centuryaluminum.com</u> Jennifer Hagedorn <u>jhagedorn@bowlesrice.com</u> John H Skaggs jskaggs@cldlaw.com

Alternative Service Concepts, LLC Alternative Service Concepts of TN, LLC

STATE OF WEST VIRGINIA WORKERS' COMPENSATION BOARD OF REVIEW

IN THE MATTER OF:

Kermit Coles, (Employee) Decedent, Wanda Coles, Dependent, CLAIMANT JCN: 2021006800 D.L.E.: May 1, 2007 D.O.D.: January 14, 2020

and

Century Aluminum of West Virginia, Inc., EMPLOYER

ORDER

PARTIES:

Claimant, Wanda Coles, by counsel, John Henry Skaggs Employer, Century Aluminum of West Virginia, Inc., by counsel, T. Jonathan Cook.

ISSUE:

The claimant protested the claim administrator's order of September 22, 2020, which denied dependents benefits.

DECISION:

It is ORDERED that the claim administrator's order of September 22, 2020, be AFFIRMED.

RECORD CONSIDERED:

See attached.

FINDINGS OF FACT:

1. The claimant, the dependent widow of the deceased employee, filed an application for dependent's benefits on April 23, 2020.

2. In his affidavit of March 24, 2021, Patrick Coles, the son of the deceased employee, asserted that he was familiar with his father's work from living with him and working with him for two years at Century Aluminum. His father worked in plant maintenance and was also assigned to the potroom as a maintenance worker on a regular



basis. In the two years that Patrick Coles was employed at the plant from 1997 to 1998, he would visit his father in the potroom. Based on his personal observations and conversations with his father, his father was present in the potroom while metals were being melted and molten product was being produced. In a subsequent Affidavit dated May 4, 2021, Patrick Coles added that he observed his father using an N-95 dust mask and half face masks but they had paper filters and not cannister type cartridges. The masks were not used during breaks and entering or leaving the building.

3. The employee's Annual Statement of his pension accounts from 1979 to 1990 was submitted into evidence. (Electronic file date January 1,1980.)

4. The Social Security Statement of Earnings of the employee from 1964 through 2007 was submitted into evidence. (Electronic file date May 5, 2008.)

5. The article entitled Cancer Risks in Aluminum Reduction Plant Workers, A Review, by Graham W. Gibbs, Ph.D., and France Labreche, Ph.D., was submitted into evidence. (Electronic file date May 1, 2014.)

6. The September 29, 2016, office clinic note from James P. Tierney, DO, CAMC Urology Surgical Center, noted that the employee presented for an evaluation of hematuria that started in January of 2016 and occurred intermittently over the past year. (Electronic file dated November 23, 2016.) The November 23, 2016, report from Dr. Tierney, indicated that the employee had a history of smoking and tobacco use and a history of occupational exposure to chemicals. In the office clinic note of May 15, 2018, the employee was seen for painful urination since April. He had a history of tobacco use seven years earlier. In the August 2, 2018, office clinic note, it was recommended that the employee have a cystoscopy and bladder biopsy.

7. The employee underwent a cystoscopy bladder biopsy at CAMC Memorial Hospital on August 13, 2018.

8. The surgical pathology report of Nadia Naumova, MD, of August 13, 2018, revealed that the employee had ulcerated urothelial mucosa with underlying moderate acute and chronic cystitis with associated reactive epithelial changes and detached strips of columnar epithelium suggestive of cystitis glandularis.

9. The employee was seen by Joshua Mark Lohri, DO, on December 13, 2018, and was assessed with detrusor overactivity and urge urinary incontinence in addition to bladder outlet obstruction and poorly compliant bladder.

10. The employee underwent a surgical procedure on December 28, 2018. The post-operative diagnosis was urge urinary incontinence overactive bladder/bladder outlet obstruction, and a bimanual pelvic examination suggested some mass effect in the left lower quadrant.

11. The employee's January 3, 2019, pelvis MRI at CAMC showed nonspecific bladder wall thickening on the left side of the bladder; infiltrating was not excluded.

12. The employee's February 15, 2019, pathology report by Oscar Cinco Estalilla, MD, identified a rectal mass as well as a urinary bladder tumor. Dr. Estalilla said the findings support a diagnosis of a high-grade urothelial carcinoma.

13. Dr. Tierney, in his February 15, 2019, History and Physical, noted that there were no changes in the claimant's condition.

14. On February 15, 2019, Dr. Tierney performed a bladder biopsy and repeat Botox.

15. The employee was seen by Nathan Edward Hale, DO, on February 21, 2019. Treatment options were discussed.

16. The employee's CT of his chest, read by Johnsey Leef, MD, on February 26, 2019, showed hyperinflated lungs with few small bullae consistent with COPD. There was non-calcified pleural plaques, calcified granulomas, and coronary artery disease.

17. Consultation notes from CAMC Cancer Center Teays Valley dated February 27, 2019, noted that the employee had bladder cancer.

18. An ultrasound was performed preoperatively on March 5, 2019. The March 5, 2019, operative report by Nathan Edward Hale, DO, at CAMC revealed that the employee had a needle nephrostogram performed.

 The April 16, 2019, pathology report from Mayo Clinic's Laboratories noted that the employee had a bladder specimen submitted.

20. On May 6, 2019, the employee was seen at Mayo Clinic by Roxana Dronca, MD, and his treatment options for his bladder cancer were discussed. His smoking history of 42 years from October 1, 1965, to February 1, 2007, was noted.

21. The May 21, 2019, preoperative medical evaluation by Nancy E. Pitruzzello, APRN, indicated that the employee would undergo an open cystoprostatectomy, bilateral pelvic lymph node dissection, and ileal conduit urinary diversion.

22. The May 24, 2019, report from Christopher McLeod, MB, CHB, Ph.D., noted that the employee had no evidence of any cardiac instability and his background coronary disease should not pose any imminent threat for upcoming non-cardiac surgery.

23. On May 30, 2019, the employee underwent an open cystoprostatecomy with ileal conduit urinary diversion and bilateral pelvic lymph node dissection at Mayo Clinic by Paul R. Young, MD.

JCN: 2021006800

24. In the progress notes of Patrick Houghton, MD, it was noted that the employee was seen on August 2, 2019; August 22, 2019; and October 22, 2019, for muscle invasive bladder cancer.

25. The employee's August 2, 2019, abdomen and pelvis CT showed some new enlarged nodes just below the renal hilum on the left and a left hydronephrosis.

26. Dr. Dronca, in her report of August 15, 2019, noted that they would proceed with a PET scan.

27. The employee's October 22, 2019, PET/CT scan was read by Ephraim Parent, MD, to show postoperative changes of cystoprostatectomy with no definite nodular hypermetabolic focus in the pelvis to suggest local recurrent disease. Continued interval decreased size of the left para-aortic lymph nodes with FDG uptake was equal to blood pool. Given the lack of interval systemic therapy, these were most consistent with resolving reactive changes. There were no hypermetabolic foci or pathologically enlarged lymph nodes on examination to suggest metabolically active disease.

28. Ahmed Bali, MD, in a discharge summary of November 20, 2019, reported that he had performed an exploratory laparotomy, small bowel resection, and open lysis of adhesions. Dr. Bali stated in his operative report of December 4, 2019, that the employee had undergone an exploratory laparotomy, small bowl resection and open lysis of inhesions.

29. Carly Rose, DO, in her consultation notes of November 28, 2019, stated the employee was seen for a palliative care consultation.

30. The employee was admitted to CAMC Hospital on November 20, 2019, and discharged on December 28, 2019, to hospice with the diagnosis of metastatic urothelial cancer with small bowel obstruction.

31. The employee was seen for a consultation with Justin David Cohen, MD, on December 9, 2019.

32. In her progress note of December 17, 2019, Dr. Dronca stated that she had discussed the employee's recent developments and spoken to his wife about the employee's recurrent metastatic urothelial carcinoma which presented with bowel obstruction and had required bowl resection.

33. The employee's lab report from CAMC Memorial Hospital on December 27, 2019, was submitted into evidence.

34. The employee's death certificate indicated that he died on January 14, 2020, with the immediate cause of metastatic urothelial cancer (bladder cancer).

35. The curriculum vitae of Charles L. Werntz, DO, dated February 10, 2021, was submitted.

36. In his April 21, 2021, record review, Dr. Werntz noted that the employee developed urinary symptoms and hematuria sometime in 2015, and in early 2019, a urothelial cancer was identified. Although the employee underwent aggressive surgical and chemotherapy treatment, the employee ultimately developed distant metastasis, including in the small bowl, and died due to this cancer. The doctor considered the employee's work in aluminum production and stated it had been determined by the International Agency for Research on Cancer (IARC) to be a class I - Known Human Carcinogen. The doctor also noted that the employee was an intermittent smoker with a 40-year smoking history and that smoking can contribute to the development of bladder cancer. Dr. Werntz reported that the analysis discussed in the IARC and a 2014 review by Gibbs and Labreche makes it clear that smokers' risk of bladder cancer is further increased by exposure to an aluminum production facility. The doctor stated that while a protective mask would certainly be helpful in reducing the risk of disease, it was unclear if the protective mask worn by the employee in this case was protective. Dr. Werntz concluded that the employee's medical records clearly documented that he was diagnosed with invasive bladder cancer in 2019 and died from this in early 2020. He worked for 27 years in an aluminum production facility as a millwright, welder, and maintenance person. Together, these jobs would have him spending most or all of his time in the aluminum production areas. In his medical opinion, the employee's development of bladder cancer was significantly contributed to by working in an aluminum production facility, including the potroom. It was his opinion that the risk of developing bladder cancer was significantly increased by the employee's work in an aluminum production facility, over what his risk would have been from his smoking habit alone. It was his further opinion that without this additional risk from the aluminum manufacturer exposure it was less likely that he would have developed bladder cancer, the ultimate cause of his death.

37. Jennifer L. Lultschik, MD, in her record review on November 21, 2022, stated that, in the 2014 review by Gibbs and Labreche, it was noted that the exposures of concern in the aluminum reduction industry were the coal tar pitch volatiles (CTPV) and polvaromatic hydrocarbons (PAH) produced in the potroom. This arises chiefly from carbon electrodes used in the process. In 2010, the IARC classified occupational exposure during carbon electrode manufacture as class 2A (probably carcinogenic to humans). Measurement of benzo(a)pyrene is typically used as an index of total PAH exposer. Gibbs and Labreche noted that the prebake potrooms have much lower exposures and risks than potrooms using the older Soderberg process. Dr. Lultschik noted that she did not have quantitation of hours of exposure to CTPV per day or week during the employee's time of employment. There was no information regarding whether Century used the "prebake" process or the "Soderberg" process. Gibbs and Labreche do note that studies in Soderberg potrooms from Canada and Norway show a strong association of exposure with bladder cancer, but they also state that bladder cancer was detected at statistically nonsignificant levels in the United States. Dr. Lultschik noted there was a strong association between tobacco smoking and bladder cancer. Dr. Lultschik felt it was more likely than not that the employee's bladder cancer was not caused by his employment at Century Aluminum.

38. The employer submitted a closing argument on December 8, 2020, which has been reviewed and considered herein.

DISCUSSION:

W.Va. Code § 23-4-1(f) provides that an occupational disease is one incurred in the course of and resulting from employment. No ordinary disease of life to which the general public is exposed outside of employment is compensable unless it is apparent "(1) that there is a direct causal connection between the conditions under which work is performed and the occupational disease, (2) that it can be seen to have followed as a natural incident of the work as a result of the exposure occasioned by the nature of the employment, (3) that it can be fairly traced to the employment as the proximate cause, (4) that it does not come from a hazard to which workmen would have been equally exposed outside of the employment, (5) that it is incidental to the character of the business and not independent of the relation of an employer and employee, and (6) that it must appear to have had its origin in the risk connected with the employment and to have flowed from that source as a natural consequence, though it need not have been foreseen or expected before its contraction."

W.Va. Code § 23-4-1 does not require the claimant to prove the conditions of his or her employment were the exclusive or sole cause of the disease nor does it require the claimant to show that the disease is peculiar to one industry, work environment, or occupation. *Powell v. State Workmen's Compensation Commissioner*, 166 W.Va. 327, 273 S.E.2d 832 (1980).

W. Va. Code § 23-4-1g provides that the resolution of any issue shall be based upon a weighing of all evidence pertaining to the issue and a finding that a preponderance of the evidence supports the chosen manner of resolution. The process of weighing evidence shall include, but not be limited to, an assessment of the relevance, credibility, materiality, and reliability that the evidence possesses in the context of the issue presented. No issue may be resolved by allowing certain evidence to be dispositive simply because it is reliable and is most favorable to a party's interests or position. The resolution of issues in claims for compensation must be decided on the merits and not according to any principle that requires statutes governing workers' compensation to be liberally construed because they are remedial in nature. If, after weighing all of the evidence regarding an issue, there is a finding that an equal amount of evidentiary weight exists for each side, the resolution that is most consistent with the claimant's position will be adopted.

Preponderance of the evidence means proof that something is more likely so than not so. In other words, a preponderance of the evidence means such evidence, when considered and compared with opposing evidence, is more persuasive or convincing. Preponderance of the evidence may not be determined by merely counting the number of witnesses, reports, evaluations, or other items of evidence. Rather, it is determined by assessing the persuasiveness of the evidence including the opportunity for knowledge, information possessed, and manner of testifying or reporting. The claim administrator denied dependent's benefits by order dated September 22, 2020. The deceased employee passed on January 14, 2020, from metastatic bladder cancer, which the dependent asserts was incurred in the course of and resulting from the employee's employment at Century. The Supreme Court, in *Powell*, determined that if studies and research clearly link a disease to a particular hazard of a workplace, a prima facie case of causation arises upon a showing that the claimant was exposed to the hazard and is suffering from the disease to which it is connected.

The claimant submitted the report of Dr. Werntz who concluded that the employee's development of bladder cancer was significantly contributed to by exposure while he was working at an aluminum production facility, including his work in the potroom. The employer submitted the report of Dr. Lultschik who noted that tobacco smoking accounts for 50% to 65% of cases of urothelial carcinoma of the bladder and is the single strongest risk factor for developing this type of cancer. The deceased employee smoked cigarettes for approximately 42 years.

The 2014 study by Gibbs and Labreche regarding the increased risk of bladder cancer in aluminum workers, was discussed by both Dr. Werntz and Dr. Lultschik. Dr. Lultschik relied on this report to support her conclusion that it is more likely than not that the employee's bladder cancer was not caused by his employment at Century. In this regard, she noted that she did not have quantitation of the hours of exposure to CTPV per day or week during the employee's time of employment and there was no information regarding whether Century used the prebake process or the older Soderberg process. Dr. Lultschik further indicated that Gibbs and Labreche noted that studies in Soderberg potrooms from Canada and Norway show a strong association of exposure with bladder cancer, but that bladder cancer was detected at statistically nonsignificant levels in the United States.

Dr. Lultschik provides more specifics about the 2014 study and the distinction in the risks for exposure to carcinogens between the "prebake" and the "Soderberg" processes. The evidence does not show which process was used by Century during the employee's time at Century, and there is no evidence regarding the extent of the employee's exposure to CTPV. Accordingly, Dr. Lultschik's report is more detailed and persuasive than the report by Dr. Werntz.

The fact that the employee worked in the aluminum plant is not alone sufficient to establish causation of his bladder cancer. Although the claimant does not have to establish that the conditions of the employee's employment were the exclusive or sole cause of the disease, she has not shown a direct causal connection between the employee's work and his development of bladder cancer. The claimant has not met her burden of proof. The order of September 22, 2020, is affirmed.

CONCLUSIONS OF LAW:

Based on preponderance of the evidence, the decedent's bladder cancer was not caused by occupational exposure at Century Aluminum.

It is, therefore, ORDERED that the claim administrator's order of September 22, 2020, be AFFIRMED.

APPEAL RIGHTS:

Under the provisions of West Virginia Code § 23-5-12a, any aggrieved party may file a written appeal within thirty (30) days after receipt of any decision or final action of the Board of Review. The appeal shall be filed with the West Virginia Intermediate Court of Appeals (304-558-3258).

Date: February 2, 2023

Allen Prunty, Board Member

CC: KERMIT COLES JOHN HENRY SKAGGS - COUNSEL FOR CLAIMANT CENTURY ALUMINUM OF WEST VIRGINIA INC T. JONATHAN COOK - COUNSEL FOR EMPLOYER DAVIES CLAIMS SOLUTIONS WANDA COLES

JCN: 2021006800

JCN: 2021006800 Date: February 2, 2023

Record Considered

Issue:

The Claimant's protest to the Claims Administrator's order of September 22, 2020, regarding DEATH BENEFITS TO DEPENDENT.

EVIDENCE SUBMITTED:

Claimant Evidence

Document Type: Document Date: Submit Date: Author: UNIO	Not Specified 1/1/1980 1/29/2021 N RECORDS/ANNUAL STATEMENT OF
Document Type: Document Date: Submit Date: Author: SOCI	ACCOUNT Not Specified 5/5/2008 1/29/2021 AL SECURITY STATEMENT EARNINGS RECORD
Document Date: Submit Date:	Not Specified 5/1/2014 5/28/2021 CLE: CANCER RISKS IN ALUMINUM REDUCTION PLANT WORKERS, A REVIEW
Document Type: Document Date: Submit Date: Author: JAME	
Document Type: Document Date: Submit Date: Author: JAME	Not Specified 8/13/2018 5/27/2021 S P. TIERNAY D.O./CAMC MEMORIAL HOSPITAL
Document Type: Document Date: Submit Date: Author: DR N/	Not Specified 8/13/2018 5/27/2021 ADIA NAUMOVA//SURGICAL PATHOLOGY REPORT

JCN: 2021006800

Kermit Coles

Document Type: Not Specified Document Date: 12/13/2018 Submit Date: 5/27/2021 Author: JOSHUA MARK LOHRI D.O./CAMC UROLOGY SURGICAL CENTER Document Type: Not Specified Document Date: 12/28/2018 Submit Date: 5/27/2021 Author: JAMES P. TIERNAY D.O./CAMC MEMORIAL HOSPITAL/ **OPERATIVE REPORT** Document Type: Not Specified Document Date: 1/3/2019 Submit Date: 5/27/2021 CAMC W&C HOSPITAL/MRI PELVIS Author: Document Type: Not Specified Document Date: 2/15/2019 Submit Date: 5/27/2021 JAMES P. TIERNAY D.O./CAMC MEMORIAL Author: HOSPITAL Document Type: Not Specified Document Date: 2/15/2019 5/27/2021 Submit Date: Author: JAMES P. TIERNAY D.O./CAMC MEMORIAL HOSPITAL/ **OPERATIVE REPORT** Document Type: Not Specified Document Date: 2/15/2019 Submit Date: 5/27/2021 Author: DR OSCAR CINCO ESTALILA/SURGICAL PATHOLOGY REPORT Document Type: Not Specified Document Date: 2/21/2019 Submit Date: 5/27/2021 Author: NATHAN EDWARD HALE D.O./CAMC UROLOGY CENTER/ OFFICE CLINIC NOTES Document Type: Not Specified Document Date: 2/26/2019 Submit Date: 5/27/2021 DR JOHNSEY LEE LEEF/CAMC IMAGING/CT Author: CHEST Document Type: Not Specified Document Date: 2/27/2019 Submit Date: 5/27/2021 Author: CAMC CANCER CENTER TEAYS VALLEY/CONSULTATION NOTES

JCN: 2021006800

Document Type: Not Specified Document Date: 3/5/2019 Submit Date: 5/27/2021 NATHAN EDWARD HALE D.O./CAMC OUTPATIENT SURGERY Author: CENTER/OPERATIVE REPORT Document Type: Not Specified Document Date: 3/5/2019 Submit Date: 5/27/2021 NATHAN EDWARD HALE D.O./CAMC OUTPATIENT SURGERY Author: CENTER/ULTRSOUND Document Type: Not Specified Document Date: 4/16/2019 Submit Date: 5/27/2021 DR OSCAR CINCO ESTALILA/CAMC MEMORIAL HOSPITAL/ Author: ADDENDUM REPORT Not Specified Document Type: Document Date: 5/6/2019 Submit Date: 5/27/2021 DR ROXANA S. DRONCA/REPORT Author: Document Type: Not Specified Document Date: 5/21/2019 Submit Date: 5/27/2021 NANCY E. PITRUZZELLO APRN/PRE OPERATIVE MEDICAL Author: **EVALUATION** Document Type: Not Specified Document Date: 5/24/2019 Submit Date: 5/27/2021 CHRISTOPHER MCLEOD MB CH/CLINICAL NOTES Author: Document Type: Not Specified Document Date: 5/30/2019 Submit Date: 5/27/2021 FREDY INSUASTY RN/OP NOTE SURGICAL LOG Author: Document Type: Not Specified Document Date: 8/2/2019 5/27/2021 Submit Date: Author: DR PATRICK HOUGHTON/OFFICE VISIT Document Type: Not Specified Document Date: 8/2/2019 Submit Date: 5/27/2021 DR PATRICK HOUGHTON/OFFICE VISIT Author: Document Type: Not Specified Document Date: 8/15/2019

JCN: 2021006800

Submit Date: 5/27/2021 Author: DR ROXANA S. DRONEA/REPORT

Document Type:Not SpecifiedDocument Date:10/22/2019Submit Date:5/27/2021Author:DR EPHRAIM PARENT/PET CT SCAN

Document Type: Not Specified Document Date: 11/20/2019 Submit Date: 5/27/2021 Author: DR AHMED BALI/DISCHARGE SUMMARY

 Document Type:
 Not Specified

 Document Date:
 11/28/2019

 Submit Date:
 5/27/2021

 Author:
 CARLY ROSE D.O./CONSULTATION NOTES

 Document Type:
 Not Specified

 Document Date:
 12/4/2019

 Submit Date:
 5/27/2021

 Author:
 DR AHMED BALI/OPERATIVE REPORT

 Document Type:
 Not Specified

 Document Date:
 12/9/2019

 Submit Date:
 5/27/2021

 Author:
 DR JUSTIN DAVID COHEN/CONSULTATION NOTES

Document Type:Not SpecifiedDocument Date:12/17/2019Submit Date:5/27/2021Author:DR ROXANA S. DRONEA/PROGRESS NOTES

 Document Type:
 Not Specified

 Document Date:
 12/27/2019

 Submit Date:
 5/27/2021

 Author:
 CAMC MEMORIAL HOSPITAL/CHEMISTRY

Document Type: Not Specified Document Date: 12/28/2019 Submit Date: 5/27/2021 Author: DR SALMAN SHAKAT/DISCHARGE SUMMARY

Document Type:Not SpecifiedDocument Date:1/14/2020Submit Date:5/27/2021Author:DEATH CERTIFICATE

 Document Type:
 Not Specified

 Document Date:
 4/23/2020

 Submit Date:
 5/27/2021

 Author:
 APPLICATION FOR FATAL DEPENDENTS

JCN: 2021006800

BENEFITS

Document Type:Not SpecifiedDocument Date:2/10/2021Submit Date:5/27/2021Author:CHARLES L. WERNTZ D.O./CURRICULUM VITAE

Document Type: Not Specified Document Date: 3/24/2021 Submit Date: 5/27/2021 Author: CLAIMANT AFFIDAVIT

Document Type: Not Specified Document Date: 4/21/2021 Submit Date: 5/27/2021 Author: CHARLES L. WERNTZ D.O./REPORT

Document Type: Not Specified Document Date: 5/4/2021 Submit Date: 5/27/2021 Author: PATRICK COLES/AFFIDAVIT

Employer Evidence

Document Type:Not SpecifiedDocument Date:5/6/2019Submit Date:11/28/2022Author:MAYO CLINIC/MEDICAL REPORTS

Document Type: Not Specified Document Date: 9/22/2020 Submit Date: 9/29/2022 Author: CLAIM ADMIN. ORDER

Document Type: Not Specified Document Date: 11/21/2022 Submit Date: 11/28/2022 Author: DR. JENNIFER L. LULTSCHIK/MEDICAL RECORDS REVIEW REPORT

CLOSING ARGUMENTS:

Party Submitted:	Employer
Letter Date:	12/8/2022





Morgantown Occupational Medicine, PLLC

Charles L. Werntz III, D.O., MPH, FACOEM, FAOCOPM 473 Devon Road Morgantown, WV 26505 304-602-2176

NAME: Kermit Coles DATE OF BIRTH: 1/4/1947 DATE OF REPORT: 4/21/2021

John Skaggs, Esq. Calwell Luce Ditrapano Roach 500 Randolph Avenue Charleston, WV 25302

Dear Mr. Skaggs,

At your request, I have reviewed the following records for Mr. Coles, and offer the following opinions. As you are aware, Mr. Coles was diagnosed with bladder cancer in 2019 and died of of metastatic urothelial (bladder) cancer in January 2020.

Work history:

- 1966 1972: US Army-truck driver-stationed at Fort Leonard Wood, Fort Ord, and in Germany.
- 1972 1980: Construction Plumber and Pipefitter (Trade Union multiple worksites and employers)
- 1980 2007: Millwright, Maintenance, and Welder Kaiser / Century / Ravenswood Aluminum

I reviewed an affidavit completed by Mr. Coles' son Patrick. He reports that Mr. Coles worked in plant maintenance, and that "after the lockout" he worked exclusively in the pot room for the rest of his career.

Mr. Coles was employed for 27 years at the Kaiser / Century / Ravenswood Aluminum plant, ending in 2007. He worked primarily performing maintenance, including a significant amount of time working in the "pot room".

An "intake form" lists the claimant's cause of death as bladder cancer. It notes his work with the United Steelworkers of America, and the Plumbers and Pipefitters local for 27 and 18 years respectively.

He worked at Century Aluminum for 27 years. His job title was millwright and maintenance person. He retired from Century Aluminum in 2007. It is reported that he spent most of his time in the pot room. They report exposure to industrial dust, heavy equipment, processing chemicals, and aluminum ore dust. He reports wearing leather boots, earplugs, glasses with side shields, and a "filtered mask".

Page 1 of 5







It is reported that Mr. Coles was a former smoker, reporting as having smoked on and off for approximate 40 years, starting in 1965.

BRIEF REVIEW OF PROVIDED MEDICAL RECORDS

On 09/26/2016 he was seen by urology with some abdominal discomfort and hematuria Intermittently over the previous year. At that point his tobacco use had ended 7 years earlier.

On 05/15/2018 he was seen by urology for painful urination.

On B/2/2018 he had cystoscopy performed which showed some posterior lateral diverticulum and concerning areas of erythema and thickening of the bladder in areas of hemorrhage adjacent to the diverticulum anteriorly.

On 8/13/2018 the claimant was seen for a cystoscopy and bladder biopsy. The surgical pathology report was interpreted as showing urothelial mucosa with underlying moderate acute and chronic cystitis with associated reactive epithelial changes, and detached strips of columnar epithelium, suggesting of cystitis of glandular origin. They note that no tumor was seen, and that the muscularis layer was not seen.

On 12/13/2018 he was seen by urology at that point their impression was of a detrusor hyperactivity and urge incontinence, in addition to bladder outlet obstruction and a poorly compliant bladder.

On 1/3/2019 he had an MRI of the left lower quadrant. They note a nonspecific bladder wall thickening of left side of the bladder, infiltrating neoplasms not excluded, noting biopsy may be necessary for further evaluation.

On 2/15/2019 he had surgery. The surgeon obtained both intravesicular and transrectal biopsy specimens of a firm rectal mass. The surgical pathology report showed invasive high-grade urothelial carcinoma with tumor invasion involving submucosal connective tissue and the muscular propria, focally.

On 2/26/2019 he had a CT scan of the chest which found a few bullae, consistent with COPD, but was otherwise negative.

I have additional detailed treatment notes from CAMC including 3/5/2019

On 5/6/2019 he was seen at the Mayo Clinic Jacksonville Florida for a comprehensive cancer evaluation. At that point he was receiving chemotherapy, and they were concerned about rectal invasion plus possible thrombophlebitis in his arm.

I have a series of pre-operative evaluations from Mayo Clinic In May 2019 include cardiovascular diseases, a comprehensive preoperative clinic evaluation, and a department of Urology evaluation.

Page 2 of 5

Scanned: 06/02/2021





On 5/30/2019 he had an open radical cystectomy with illial conduit urinary diversion, bilateral pelvic lymph node dissection (N/A). The pre- and post-operative diagnosis was of malignant neoplasm of the bladder. The final pathologic determination was that the ureters were negative for tumor, the right pelvic lymph nodes positive for 1 out of 10 positive, bladder and prostate was negative for residual urothelial carcinoma, and the left pelvic lymph nodes were 1 out of 5 positive for carcinoma.

Additional records from Mayo Clinic 8/6/2019, 8/22/2019, 10/22/2019, at which point they were not able to identify active disease on PET scan.

On 11/20/2019 he was evaluated at CAMC Memorial, and it appears that the primary cause was a small bowel obstruction, in addition to his high-grade cancer. On 12/28/2019 the discharge note from the hospital notes small bowel obstruction secondary to underlying metastatic urothelial cancer. He was discharged into hospice on comfort measures. During the hospitalization on 11/29/2019 he had surgery for a high-grade small bowel blockage. The surgeon's impression was that it was notably thick and stenotic and most likely metastasis from the primary bladder cancer. The notes in this admission ends with an evaluation by Palliative care, although they were still waiting for the pathology from the bowel resection.

The death certificate documents his death on 01/14/2020. The listed cause of death is metastatic urothelial cancer (bladder cancer).

DISCUSSION

In summary, this claimant developed urinary symptoms and hematuria sometime in 2015. Unfortunately, this was difficult to diagnosis, slowed by a negative biopsy. In early 2019 a repeat biopsy was performed and identified a urothelial cancer. Although he underwent aggressive surgical and chemotherapy treatment, he ultimately developed distant metastasis, including in the small bowel, and died due to this cancer.

The question at hand relates to causation of his bladder cancer. This claimant had several potential contributing factors to his developing bladder cancer, including his smoking history and his work at Century Aluminum (and successor companies) at the Ravenswood, WV aluminum production facility.

Working in aluminum production has been determined by the International Agency for Research on Cancer (IARC) to be a class 1 - Known Human Carcinogen. IARC will periodically update their assessments, and their most recent review of current data and opinion on cancer in aluminum production workers is found in Monograph 100F-22 (2018)¹. They concluded:

There is sufficient evidence in humans for the carcinogenicity of occupational exposures during aluminium production. Occupational exposures during aluminium production cause cancer of bladder, and of the lung.

Reading IARC Monograph 100F-22 carefully, there are several key points relevant to this claimant. First is that their conclusions reflect the entirely of aluminum production, and

Page 3 of 5

Scanned: 06/02/2021





that there is insufficient data to identify specific individual exposures, aspects of aluminum production, or particular chemical agents that are causative. Second, that there are several apparent carcinogens present in aluminum production, including PAH, potroom dust, and benzo(a)pyrene. In studies of exposed workforces, the elevated bladder cancer risk was seen across the production activities. Finally, several Canadian studies of aluminum workers they note that the elevated risk of bladder cancer persists, even when corrected for smoking status.

In a 2014 review of this topic², Gibbs and Labrèche concluded that the increased risk of bladder cancer persisted despite smoking status. They associated this risk with the levels of Benzo(a)pyrene in air, as a surrogate for PAH levels.

In addition to his workplace exposures, this claimant was also an intermittent smoker with a 40 year smoking history. Smoking can contribute to the development of bladder cancer, however, the analysis discussed in the IARC¹ and Gibbs and Labrèche² publications makes it clear that even in smokers the risk of bladder cancer is further increased by exposure to an aluminum production facility.

A final aspect that must be considered is the use of a "protective mask". There are several reports that this claimant did use a protective mask, at least for a portion of his career at Century Aluminum. There are no specific notes on what type of protective mask this may have been. Assuming that the protective mask was at least an N-95 respirator, this would provide protection from particulate portions of air contamination within the plant. To provide protection from the aromatic portions of the air contamination, a respirator with an organic vapor cartridge would be needed. Assessing the degree of protection provided by the respirator requires knowing what portion of the time it was worn. While 100% wearing of a respirator with a perpetually "fresh" organic vapor cartridge whenever in the aluminum production facility would yield good protection, any deviation from this would decrease the degree of protection and result in increased bladder cancer risk. This would include work time without the respirator, especially in the summer when the pot room can be especially hot, entering production areas before fully donning the respirator, or the use of a respirator cartridge beyond the usable service life. Of note, organic vapor cartridges use activated charcoal to "capture" the organic vapors before they are inhaled. The activated charcoal can absorb for only a limited time before it becomes "saturated", and is no longer protective. How this issue was addressed by the employer would have significant impact on how "protective" the respirator would be against organic vapors like PAH and benzo(a)pyrene, and how much risk would still exist. even with respirator use.

In conclusion, while use of a protective mask would certainly be helpful in reducing risk, it is unclear if a protective mask worn by this claimant was protective, and as typically used would almost certainly not be 100% protective from exposure to the bladder cancer risk associated with volatile organics from aluminum production activities.

Assessment of causation is the key factor in this matter. The best accepted approach is to use Hill's criteria. While several aspects apply only to populations, there are several aspects of Hill's Criteria that were assessed in assessing causation on this individual.

Page 4 of 5

Scanned: 06/02/2021





Temporality – Mr. Coles developed bladder cancer after exposure to the aluminum production activities, and with an appropriate latency period between the onset of exposure and development of disease.

Biologic Plausibility – There is a robust literature associating Bladder Cancer with PAH exposure, as well as exposure in aluminum production facilities.

Specificity & Consistency – The IARC monograph notes an association between aluminum production facilities and bladder and lung cancers, specifically. This claimant suffered from Bladder Cancer, one of these specific cancers.

MEDICAL OPINION

Mr. Coles' medical records clearly document that this gentleman was diagnosed with invasive bladder cancer in 2019 and died from his bladder cancer in early 2020. Mr. Cole worked for 27 years in an aluminum production facility as a millwright, welder, and maintenance person. Together these jobs would have had him spending most or all of his time in the aluminum production areas.

It is my medical opinion that Mr. Coles' development of bladder cancer was significantly contributed to by his working in an aluminum production facility, including the potroom. Based upon the literature, it is my opinion that his risk of developing bladder cancer was significantly increased by his work in an aluminum production facility over what his risk would have been from smoking habit alone. It is my further opinion that without this additional risk from the aluminum manufacturing exposures it is less likely that he would have developed bladder cancer, the ultimate cause of his death.

Charles L Werntz III, D.O., MPH, FACOEM, FAOCOPM

IARC Monograph 100F-22, <u>https://monographs.iarc.fr/wp-content/uploads/2018/Q6/mono100F-22.pdf</u>, viewed 19 April 2021.

² Gibbs GW, Labrèche F, Cancer risks in aluminum reduction plant workers: a review. J Occup Environ Med, 2014 May;56(5 Suppl):S40-59. PMID: 24806725; PMCID: PMC4131938.

Page 5 of 5

Workers' Compensation Board of Review P.O. Box 2628 Charleston, WV 25329-2628 (304) 558-5230

Document Submission Form

Claimant: Kermit Cole (deceased)

Employer(s): Century Aluminum of West Virginia

JCN No: 2021006800

Carrier Ref. No.: C6720710144-01

DOI/DLE: 5/01/2007

Submitting Party: T. Jonathan Cook, Esq. Representing Employer

Reference: September 22, 2020

Short Description(s) of Order: Denied death benefits

Please Select One of the Following Categories: Attach only (1) document per form

Evidence: Record Review report of Dr. Jennifer Lultschik dated November 21, 2022

Date: November 28, 2022

Submitted by:

WV Bar-1D # 9057

T. Jonathan Cook, Esq.

TJC/mm

Enclosure

cc: John H. Skaggs, Esquire Davies, Doniela Fiato (via e-mail) Century Aluminum of West Virginia (via e-mail)



WVU OCCUPATIONAL MEDICINE P.O. BOX 9145 MORGANTOWN, WV 26505-9145 304-293-3693

Claimant: Kermit Coles (deceased); DOB: 01/04/1947 DOI: 5/01/2007 Insured: Century Aluminum of West Virginia, Inc. Claim No.; C6729710144-01

MEDICAL FILE REVIEW

Date: 11/21/2022

Cipriani & Werner Attorneys at Law 500 Lee Street East, Suite 900 Charleston, WV 25301

Attention: T. Jonathan Cook, Esq.

Dear Attorney Cook,

As requested in your letter of 10/31/2022, I have performed a medical review concerning the above-referenced individual.

I have reviewed the following documents that you provided:

- 1. Mayo Clinic medical records including H&P notes, progress notes, lab and diagnostic test results, operative reports, and pathology reports, 1,487 pages.
- 2. Administrative documents providing claimant's work history, submitted by Dependent.
- 3. Application for Dependent's Benefits dated 4/23/2020.
- 4. Denial of claim dated 9/22/2020.
- 5. Affidavits, Patrick Coles, dated 3/24/2021 and 5/04/2021.
- Charleston Area Medical Center (CAMC) Urology medical records and discharge summary dated 11/23/2016 through 12/28/2019.

File Summary:

From the documents completed by the Dependent, Mr. Coles served in the Army as a truck driver from 5/25/1966 through honorable discharge on 5/24/1972. He was stationed at Fort Leonard Wood, Fort Ord, and in Germany during that time.

He then worked out of the United Steelworkers of America Local 5668 for 27 years, and the Plumbers and Pipefitters Local 625 for 18 years. He took regular retirement in May 2007. During his working career he worked as a pipefitter and welder, and as a millwright.

On the document outlining occupational exposures, asbestos (during construction jobs), industrial dust, loud or heavy equipment, processing chemicals, and aluminum ore dust were listed. The employer in question was noted as Century and the duration was noted as 27 years. Personal protective equipment worn included leather work boots, ear plugs, safety glasses with side shields, and filter masks.

Documents note employment through Pipefitters Local 625 as a pipefitter and welder from 1970 to 1990. The document listing Century Aluminum in Ravenswood, WV notes a work history of 27 years, the job position as 'Millwright – Maintenance', and the location as 'potroom'. Exposure to ore dust was reported, and the document stated that filter mask and safety glasses were worn 'all the time'.

A list of employment sites provided by the Dependent includes American Viscose/FMC/Avtex in Nitro, WV, Ashland Oil & Chemical in KY or WV, Du Pont Chemical in Bella, WV, FMC Corporation/Ohio Apex in Nitro, WV, Kaiser/Ravenswood Aluminum in Ravenswood, WV, Monsanto Chemical in Nitro, WV, UCC/Bakelite in Alloy, WV, Union Carbide in Institute, WV, John Amos Power Plan in Winfield, WV, and Perry Nuclear Power Plant in Perry, OH for 10 months. Question marks were placed beside Union Carbide Chemical in South Charleston, WV.

No duration of work or job description, and no information regarding type of exposure, exposure duration per week, or level of exposure was provided for any employment location other than the statement of 27 years spent at Ravenswood, WV. No information regarding hours/shift and shifts/week was available, and no information regarding type and frequency of tasks in the potroom at Ravenswood was available.

Affidavits from Mr. Patrick Coles, son of Mr. Kermit Coles, are dated 3/24/2021 and 5/4/2021. The earlier affidavit states that Mr. Patrick Coles worked at Century Aluminum in security and as a firefighter and EMT for 2 years from 1996 to 1998. He states in the affidavit that he would visit his father in the potroom and observe him present there, and that based on his observation and conversations with his father, Mr. Kermit Coles was employed in the potroom on a regular basis throughout his years of employment, and continuously 'after the lockout'. Mr. Patrick Coles further states that his father was present when metals were being melted and molten material produced. The dates of the lockout are not provided. The affidavit of 5/4/2021 contains the same information, with the addition of a statement that N95 masks and 'half-face devices' with paper filters were used by his father and other employees during work hours, although not while entering and exiting the workplace nor while donning and doffing the masks.

Mr. Kermit Cole was noted to have a history of coronary artery disease with episodes of coronary artery spasm for which he saw Dr. H. Stanton on 2/01/2007. He had cataract surgery on both eyes with Dr. L. Minardi and had had some inner ear problems. His primary care physician was Dr. C. Bowman of Dunbar Medical Associates.

Mr. Coles was seen at CAMC Urology on 11/23/2016 for benign prostatic hypertrophy (BPH) and in follow-up of an episode of gross hematuria in June 2016. The history notes that he had a history of being a 'heavy tobacco smoker'. Office cystoscopy showed an enlarged prostate, with varices noted and otherwise normal uroepithelium. A recent CT urogram had been negative for pathology. Use of Proscar and Flomax was recommended for Mr. Cole's urinary tract symptoms.

The CAMC Urology note dated 9/29/2016 states that Mr. Coles had had intermittent hematuria dating from January 2016, and now had right lower quadrant discomfort that was attributed to passing a renal stone.

At his annual CAMC Urology follow-up for BPH on 5/15/2018, Mr. Coles reported burning with urination and aching between the scrotum and rectum since April 2018; this improved with a course of antibiotics.

Mr. Coles underwent an office cystoscopy on 8/02/2018, at which time concerning areas of thickened uroepithelium, erythema, and hemorrhage were noted. The office procedure was discontinued and a cystoscopy in the OR with bladder biopsy was planned. On 8/13/2018 this was performed and the anterior bladder wall was biopsied. Pathology showed ulcerated urothelial mucosa with acute and chronic cystitis and suggestion of cystitis glandularis. No tumor was seen.

Mr. Coles continued to have symptoms of overactive bladder and urge incontinence, and cystoscopy was repeated on 12/28/2018. Manual exam on that date suggested a mass effect in the left lower quadrant, and Botox injection could not be performed on the left side of the bladder. Further imaging was recommended.

On 01/03/2019 Mr. Coles underwent MRI of the pelvis; the report notes nonspecific bladder wall thickening on the left side, infiltrating neoplasm not excluded. Mr. Coles then underwent cystoscopy and bladder biopsy on 2/15/2019. The left side of the bladder appeared distorted and exhibited varicosities, bullous edema, and erythematous patches. Two representative areas were resected, and after digital rectal exam was abnormal, a needle core biopsy of a rectal mass was performed. The surgical pathology report of the same date notes high-grade urothelial carcinoma with tumor invasion of the submucosal connective tissue and the muscular propria. In the rectal biopsy, cores of urothelial carcinoma infiltrating the muscle propria and fibrocollagenous tissue were present.

CT of chest performed on 2/26/2019 showed hyperinflated lungs with some small bullae consistent with COPD. Calcified granulomas and noncalcified pleural plaques were present. No metastatic disease was seen.

Mr. Coles was evaluated by Dr. N. Hale, DO, Oncology at CAMC on 2/27/2019. Neoadjuvant chemotherapy was recommended prior to surgical management. Mr. Coles could not tolerate cisplatin due to elevated creatinine levels, and a regimen of gemcitabine and paclitaxel given 3 weeks on, 1 week off was used instead. Bilateral nephrostomy tubes were placed on 3/5/2019

and chemotherapy began on 3/8/2019. His treatment was complicated by neutropenia and urinary tract infection. His last chemotherapy treatment was given on 5/3/2019.

Mr. Coles then presented to Dr. R. Dronca, MD, at the Mayo Clinic in Jacksonville, Florida on 5/6/2019 for a second opinion on choice of surgery. A more extensive surgery involving removal of the rectum vs cystectomy alone had been proposed at CAMC. He reported concerns about left arm and forearm swelling and hardening, and concern for burning rectal discomfort. The history noted that Mr. Coles was a former smoker, having smoked cigarettes for 42 years with a start date of 10/01/1965 and a quit date of 02/01/2007. Dr. Dronca ordered MRI of abdomen and pelvis and a sigmoidoscopy to evaluate rectal tumor invasion.

On 5/30/2019 Mr. Coles underwent open cystoprostatectomy with ileal conduit urinary diversion and bilateral pelvic lymph node dissection at the Mayo Clinic. The operative note describes the tumor as filling most of the pelvis, spreading in nature, and difficult to completely resect.

CT urogram performed on 8/2/2019 showed new moderate left-sided hydroureteronephrosis, and a stricture was suspected. Mr. Coles then underwent CT of abdomen and pelvis without contrast the same day. Interval development of moderate left hydronephrosis and left hydroureter to the level of the ilial conduit was seen. Interval development of left para-aortic adenopathy was noted and follow-up with CT was recommended.

At follow-up with Mayo Clinic Oncology on 10/22/2019, Dr. Dronca reviewed the recent PET scan with Mr. Coles and his wife. She saw no evidence of recurrent progressive disease, and the para-aortic lymph nodes had improved to the point of having normal levels of uptake. Due to their regression, they were considered reactive in nature.

On 11/20/2019 Mr. Coles presented to the CAMC Emergency Department with a one-week history of abdominal pain, distension, and inability to have a bowel movement. He was admitted to hospital after CT scan was concerning for small bowel obstruction, and a nasogastric (NG) tube was placed. He had some improvement with conservative management, but then had recurrence of abdominal pain. A small bowel follow-through study showed a high-grade small bowel obstruction (SBO). After obtaining a second opinion regarding surgical management, Mr. Coles underwent laparotomy at CAMC on 11/29/2019, at which time a lesion in the small bowel wall causing blockage was seen. The involved small bowel, about 30 cm in length, was resected. The appearance was suggestive of metastatic disease from bladder carcinoma.

Mr. Coles was discharged from CAMC on 12/28/2019 and transferred to Hubbard House Hospice. His wife, Wanda Coles, messaged Dr. Dronca with updates regarding poor prognosis in December, as Mr. Coles was too weak to tolerate further treatment. His date of death was 1/14/2020.

In answer to your specific questions:

 Based on your review of the claim records, please state whether the medical and other evidence supports the claimant's allegation that the claimant's bladder cancer was caused by working at Century Aluminum. Please state with specificity the basis for your opinion.

In their 2014 review, Gibbs and Labreche noted that the exposures of concern in the aluminum reduction industry are the coal tar pitch volatiles (CTPV) and polyaromatic hydrocarbons (PAH) produced in the potroom. These arise chiefly from the carbon electrodes used in the process. In 2010 the IARC classified 'occupational exposures during carbon electrode manufacture' as Class 2A (probably carcinogenic to humans). Measurement of benzo(a)pyrene is typically used as an index of total PAH exposure.¹

Gibbs and Labreche noted that prebake potrooms have much lower exposures and risks than potrooms using the older Soderberg process.^{1,2} They also noted that soot and coal tar pitch have been associated with limited human evidence for bladder cancer risk. They report that while studies have shown significant increased risk from exposure in Soderberg potrooms in Canada and Norway, no significant change in risk of bladder cancer was seen in the United States and France. They state, "There was no excess of bladder cancer deaths in workers ever employed in the potrooms or carbon plants in the US studies."¹

The documents provided to me for review do not include a detailed job description of Mr. Coles's work at Century, nor quantitation of hours of exposure to CTPV per day or week during his time of employment there. There is no information regarding whether Century used the 'prebake' process or the 'Soderberg' process. Gibbs and Labreche do note that studies in Soderberg potrooms from Canada and Norway showed a strong association of exposure with bladder cancer, but they also state that bladder cancer was "... detected at statistically nonsignificant levels in the United States ...".

There is a strong association between tobacco smoking and bladder cancer. Freedman *et al* noted that the medical literature placed the population-attributable risk for tobacco smoking and bladder cancer at 50-65%, meaning that tobacco smoking accounts for 50-65% of bladder cancer cases in men.³ Their own study confirmed a population-attributable risk for smoking of 50%. Smoking is recognized as the single greatest risk factor for urothelial carcinoma of the bladder.³

Welty *et al* examined persistence of elevated risk of bladder cancer after smoking cessation; they found that the hazard ratio (HR) for bladder cancer in those with a 37.5 or more pack-year history of smoking was 2.77 (95% CI 2.00-3.85), and those who were less than 14 years since quitting tobacco smoking at the time of bladder cancer diagnosis had a HR of 2.52 (95% CI 1.79-3.53).⁴ From the medical record, Mr. Coles had a 42-year smoking history (1965 through 2007) and was known to be a 'heavy smoker'. A conservative estimate of 'heavy smoking' would be 1 pack per day; this would result in a 42 pack-year smoking history, with a hazard ratio of 2.77 as noted above. Welty also noted that an increased risk of urothelial carcinoma (UC) of the bladder

persisted more than 32 years after quitting, and said, "This argues that a history of smoking should continue to be considered a strong risk factor for UC throughout a person's life."

Tobacco smoking accounts for 50-65% of cases of urothelial carcinoma of the bladder, and is the single strongest risk factor for this cancer. While there is some evidence to support an association between exposure to polyaromatic hydrocarbons (PAH) and CPTV in Soderberg potrooms in Canada and Norway and bladder cancer, there have been no excess bladder cancer deaths in US studies. From the available information it is not possible to estimate the extent and duration of exposure sustained by Mr. Coles, or whether he worked in a Soderberg potroom. On the other hand, Mr. Coles's 42+ pack-year tobacco smoking exposure places him at significantly increased risk for urothelial carcinoma of the bladder, is a sufficient causative factor without any other exposure, and in my opinion is more likely than not the cause of his bladder cancer.

To answer your question, in my opinion it is more likely than not the claimant's bladder cancer was not caused by his employment at Century Aluminum.

The above opinions are given within a reasonable degree of medical certainty and within the scope of my medical specialty, Occupational Medicine, and are based on information currently available to me. If additional information is provided I reserve the right to take such information into account and may alter my opinions in this matter. Thank you for the opportunity to review this file.

Thank you for asking me to assess this claimant.

Yours truly,

L. hultscherk MD

Jennifer L. Lultschik, MD, MPH, FACOEM Assistant Professor, WVU School of Public Health Department of Occupational & Environmental Health Sciences WVU Occupational Medicine

References:

- Gibbs, Graham W. PhD; Labrèche, France PhD. Cancer Risks in Aluminum Reduction Plant Workers: A Review. Journal of Occupational and Environmental Medicine: May 2014 - Volume 56 - Issue - p S40-S59.
- Kvande, Halvor PhD, MSc. The Aluminum Smelting Process. Journal of Occupational and Environmental Medicine: May 2014 - Volume 56 - Issue - p S2-S4.
- Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17;306(7):737-45.

 Welty CJ, Wright JL, Hotaling JM, Bhatti P, Porter MP, White E. Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. Urol Oncol. 2014 Jan;32(1):25.e21-5. doi: 10.1016/j.urolonc.2012.09.001. Epub 2013 Mar 15.

Workers' Compensation Board of Review P.O. Box 2628 Charleston, WV 25329-2628 (304) 558-5230

Document Submission Form

Claimant: Kermit Cole (deceased)

Employer(s): Century Aluminum of West Virginia

Employer

JCN No: 2021006800

Carrier Ref. No.: C6720710144-01

DOI/DLE: 5/01/2007

Submitting Party: T. Jonathan Cook, Esq. Representing

Reference: September 22, 2020

Short Description(s) of Order: Denied death benefits

Please Select One of the Following Categories: Attach only (1) document per form

Evidence: Select medical records received from Mayo Clinic

Date: November 28, 2022

Submitted by:

T. Jonathan Cook, Esq. WV Bar +D # 9057

TJC/mm

Enclosure

cc: John H. Skaggs, Esquire Davies, Doniela Fiato (via e-mail) Century Aluminum of West Virginia (via e-mail)





05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida

Visit Information

ason for Visit							in Jack	sonville, Florida
05/06/2019 2359	Home Or S	the second se	None		None		Depart	ment of Radiology
Discharge Date/Tin	ne Discharge	Disposition	Discharge I	Destination	Discha	rge Provider	Unit	
Discharge Information								
Admit Provider:		Attendi	ng Provider:	Dronca, Ro: M.D.	xana S,	Referring Provide	r: Dro M.	cksonville, Florida onca, Roxana S, D.
Transfer Source:		Service	Area:	MAYO CLIN SERVICE A	11.00	Unit:	Ra	partment of diology in
Means of Arrival:			Service:			Secondary Servic	e: N//	4
	LIGCUVE			Non-health Facility Poir Origin		Admit Category:		
Arrival Date/Time: Admission Type:	Elective		Date/Time: f Origin:	05/06/2019		IP Adm. Date/Tim	e:	

٠

Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder Lateral Wall [C67.2] .

Clinical Notes

No documentation.



05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida (continued)

Case 1502525983

General Information			
Date: 5/6/2019 Location: FLA RAD JADV Patient class:	Time: Room: Case classification:	Status: Unposted Service:	
Diagnosis Information			
No post-op diagnosis codes associa	ted with the log.		
			_
nical Documentation Case Tracking Events Event		Time In	
Case Tracking Events		Time In 1547	
Event			
Case Tracking Events Event In Facility			

None



05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida (continued)

jing			
JS Upper Extremity Veins Left [222	2487092938] (Final result)		
Electronically signed by: Dronca, Ro: This order may be acted on in anothe Ordering user: Dronca, Roxana S, M. Authorized by: Dronca, Roxana S, M. Frequency: RAD - Routine (most inpa Once 05/06/19 1547 - 1 occurrence Quantity: 1 Instance released by: Barry, Judene I Diagnoses Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder Later Provider Details	er encounter, D, 05/06/19 0930 D. atients and all outpatients) L 5/6/2019 3:47 PM	30 Ordering provider: Dronca, Rox Ordering mode: Standard Class: Ancillary Performed Lab status: Final result	Status: Complete
Provider		NDI	
Dronca, Roxana S, M.D.		NPI 1092657052	
		1982657052	
Questionnaire			
Question		Answer	
Clinical question to be answered		left arm pain and swelling	
Region;		Florida Region	
Screening Form			
General Information			
Patient Name: Coles, Kermi Date of Birth: 1/4/1947 Sex Assigned at Birth: Male		MRN: 12-297-754 Home Phone: 304-610-538 Mobile: 304-610-5386	36
Procedure	Ordering Provider	Authorizing Provider	Appointment Information
US UPPER EXTREMITY VEINS LEFT	Dronca, Roxana S, M.D. 904-953-2607 7833821	Dronca, Roxana S, M.D. 904-953-2607 7833821	5/6/2019 4:00 PM US JADV 02 RM 03 FLA RAD US JADV 02
Screening Form Questions			
No questions have been an: Begin Exam Questions	swered for this form.		
	Answer	Comm	lent
Line on the schedule:	4801 US LOS FL	A	
End Exam Questions			
	Answer	Comm	ient
Patient Holder?	7410101	Comm	IGHL
Patient Holder name(s)			
Rad tech student name?			
Line on the schedule:	4801 US LOS FL	Α	
	1001 00 20012		



05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida (continued)

Imaging (continued) Ordering provider: Dronca, Roxana S, M.D. 05/06/19 1547 Order status: Completed Filed by: Interface, Mc In Orm_Oru Radiology Generic 609311 Resulted by: Sella, David M, M.D. 05/06/19 1629 Performed: 05/06/19 1618 - 05/06/19 1619 Accession number: 11162798 Resulting lab: POWERSCRIBE360 Narrative: EXAM: US UPPER EXTREMITY VEINS LEFT EXAM: US UPPER EXTREMITY VEINS LEFT COMPARISON: No comparisons available. FINDINGS: Ultrasound examination of the left upper extremity was performed using duplex color and spectral Doppler, grayscale imaging and compression where possible. There is no evidence for deep venous thrombosis in the left internal jugular, innominate, subclavian, axillary and brachial veins. Acute thrombus is identified in the cephalic vein in the upper arm and forearm. Acute thrombus is identified in the basilic vein in the upper arm. Waveforms show no evidence for more central stenosis. Contralateral waveforms in the right internal jugular and subclavian veins are normal and symmetric. Case discussed with Dr. Dronca 5/6/2019 at 1625 hours Impression: IMPRESSION: Acute superficial thrombus involving the cephalic vein in the forearm and upper arm. Acute superficial thrombus involving the basilic vein in the upper arm. No DVT. Acknowledged by: Dronca, Roxana S, M.D. on 05/06/19 1821 **Testing Performed By** Lab - Abbreviation Name Director Address Valid Date Range 216 - PS360 POWERSCRIBE360 Unknown NA 08/03/16 1155 - Present Signed Electronically signed by Sella, David M, M.D. on 5/6/19 at 1626 EDT **All Reviewers List** Dronca, Roxana S, M.D. on 5/6/2019 18:21 Labs No documentation.

Medication List

Medication List

This report is for documentation purposes only. The patient should not follow medication instructions within. For accurate instructions regarding medications, the patient should instead consult their physician or after visit summary MAYO CLINIC Coles, Kermit William MRN: 12-297-754, DOB: 1/4/1947, Sex: M Adm: 5/6/2019, D/C: 5/6/2019

05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida (continued)

Medication List (continued)

oratadine (CLARITIN) 10 mg tablet	and the second se
Discontinued by: Bowles, Desiree D, R.N.	Discontinued on: 5/22/2019
Instructions: Take 10 mg by mouth 5 (five) times a week. M-F Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
isosorbide mononitrate (IMDUR) 30 mg 24 hr tablet	
Instructions: Take 30 mg by mouth daily. Entered by: Ray, Amanda C	Entered on: 5/6/2019
multivit with min-folic acid (MEN'S MULTIVITAMIN GUMMIES	5) 200 mcg tablet,chewable
Instructions: Chew 200 mg daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
omeprazole (PriLOSEC) 40 mg DR capsule	
Discontinued by: Bowles, Desiree D, R.N.	Discontinued on: 5/22/2019
Instructions: Take 40 mg by mouth 2 (two) times a day. Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
inasteride (PROSCAR) 5 mg tablet	
Instructions: Take 5 mg by mouth daily.	Contraction and the second
Entered by: Ray, Amanda C	Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA-3, F	F.) 0.5-1-0.5 % dropperette
Instructions: Administer into both eyes 2 (two) times a day.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable tabl	at
Instructions: Chew 500 mg daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
simvastatin (ZOCOR) 20 mg tablet	
Instructions: Take 20 mg by mouth at bedtime.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
polyethylene glycol-electrolytes (GoLYTELY) 236-22.74-6.74	-5.86 gram solution
	of prep following morning starting at 0500 and finish before
in the second second second black and a second s	Ordered on: 5/6/2019
appointment, as directed.	0/08/80 00: 5/6/2019
appointment, as directed. Authorized by: Dronca, Roxana S, M.D.	
appointment, as directed.	End date: 5/7/2019 Refill: No refills remaining
appointment, as directed. Authorized by: Dronca, Roxana S, M.D. Start date: 5/6/2019	End date: 5/7/2019

12/30/2021 3:52 PM EST



05/06/2019 - Ultrasound Vascular Exam in Department of Radiology in Jacksonville, Florida (continued) Medication List (continued)

05/07/19 0224	
53	



05/06/2019 - Clinical Communication in Department of Radiology in Jacksonville, Florida

Visit Information

Provider	Int	ormation	
-			_

Encounter Provider Manning, Stacey A, APRN, D.N.P.

Department

Name
Department of Radiology in
Jacksonville, Florida

Address 4500 SAN PABLO RD S Jacksonville FL 32224-1865

Phone

904-953-2000

Fax 904-953-1044

Clinical Notes

Telephone Encounter

Author: Manning, Stacey A, APRN, D.N.P.	Service: RAD (Radiology)	Author Type: Nurse Practitioner
Filed: 5/6/2019 11:27 AM Editor: Manning, Stacey A, APRN, D.N.	Encounter Date: 5/6/2019 P. (Nurse Practitioner)	Status: Signed

You placed an order for an IR clinic consult. This is currently scheduled in 2 days on 5/8. From looking at your note, it looks like you are wanting his nephrostomy tubes evaluated. This is an order you place for him to go directly to the procedure: IR Nephrostomy tube exchange. You can put in notes bilateral, what the issue is, etc. His clinic consult should be cancelled. Thanks so much.

Stacey Manning, DNP

Electronically Signed by Manning, Stacey A, APRN, D.N.P. on 5/6/2019 11:27 AM

Imaging

No documentation.

Labs

No documentation.

Medication List

Medication List

This report is for documentation purposes only. The patient should not follow medication instructions within. For accurate instructions regarding medications, the patient should instead consult their physician or after visit summary.

Active a	at the	End of	Visit
----------	--------	--------	-------

loratadine (CLARITIN) 10 mg tablet

Discontinued by: Bowles, Desiree D, R.N. Instructions: Take 10 mg by mouth 5 (five) times a week. M-F Entered by: Ray, Amanda C End date: 5/22/2019

Discontinued on: 5/22/2019

Entered on: 5/6/2019



05/06/2019 - Clinical Communication in Department of Radiology in Jacksonville, Florida (continued)

Medication List (continued)

sosorbide mononitrate (IMDUR) 30 mg 24 hr tablet	
Instructions: Take 30 mg by mouth daily. Entered by: Ray, Amanda C	Entered on: 5/6/2019
multivit with min-folic acid (MEN'S MULTIVITAMIN GUM	IMIES) 200 mcg tablet,chewable
Instructions: Chew 200 mg daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
omeprazole (PriLOSEC) 40 mg DR capsule	
Discontinued by: Bowles, Desiree D, R.N.	Discontinued on: 5/22/2019
Instructions: Take 40 mg by mouth 2 (two) times a day.	
Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
inasteride (PROSCAR) 5 mg tablet	
Instructions: Take 5 mg by mouth daily.	the second se
Entered by: Ray, Amanda C	Entered on: 5/6/2019
Entered by: Ray, Amanda C carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C	A-3, PF,) 0.5-1-0.5 % dropperette
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C Simvastatin (ZOCOR) 20 mg tablet	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C aimvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime. Entered by: Ray, Amanda C bolyethylene glycol-electrolytes (GoLYTELY) 236-22.74-	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet Entered on: 5/6/2019 Entered on: 5/6/2019 6.74 -5.86 gram solution
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime. Entered by: Ray, Amanda C bolyethylene glycol-electrolytes (GoLYTELY) 236-22.74- Instructions: Take 50% of prep night before by 10 pm and 1	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet Entered on: 5/6/2019 Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime. Entered by: Ray, Amanda C bolyethylene glycol-electrolytes (GoLYTELY) 236-22.74- Instructions: Take 50% of prep night before by 10 pm and 5 appointment, as directed. Authorized by: Dronca, Roxana S, M.D.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet Entered on: 5/6/2019 Entered on: 5/6/2019 6.74 -5.86 gram solution
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime. Entered by: Ray, Amanda C bolyethylene glycol-electrolytes (GoLYTELY) 236-22.74- Instructions: Take 50% of prep night before by 10 pm and 5 appointment, as directed.	A-3, PF,) 0.5-1-0.5 % dropperette Entered on: 5/6/2019 tablet Entered on: 5/6/2019 Entered on: 5/6/2019 6.74 -5.86 gram solution 50% of prep following morning starting at 0500 and finish before

Stopped in Visit

None



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida

ppointment Informa	tion		
LAB TEST URINE 5/6/2019 10:30 AM		Completed	
Time	Provider	Department	Length
10:30 AM	LAB URINE 01 JAMG	FLA LAB JAMG	10 mir
Referral Provider:	DRONCA, ROXANA S	Arrival Time: 10:17 AM	
History	11.1. 1.2. C		
Made On:	5/6/2019 9:51 AM	By: Margol, Gabrielle H	ES
Checked In:	5/6/2019 10:17 AM	By: Pickett, Victoria R	ES
EOD Status:	5/10/2019 2:46 AM	By: Cadence,Batch Job	ES

Reason for Visit

Visit Diagnoses

- Pain Rectal [K62.89]
- Malignant Neoplasm Of Bladder Lateral Wall [C67.2]
- Mass Rectum [R19.09]

Clinical Notes

No documentation.

Imaging

No documentation.

Labs

Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 0940 This order may be acted on in another encounter. Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - Quantity: 1 Instance released by: Pickett, Victoria R 5/6/2019 10:17 AM Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2] Mass Rectum [R19.09] Provider Details	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect Lab status: Final result	Status: Completed
Provider	NPI	




05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Dronca, Roxana S, M.D.		1982657052		
Questionnaire				
Question		Answer		
Region:		Florida Region		
Specimen Information				
ID Type	Source	Second Second	Collected By	11
E006010851:1 Urine	Urine, Cle	an Catch	05/06/19 1029	9
Urinalysis with Microscopic: Urine (Abnormal)	, Clean Catch [2222487092		ulted: 05/06/19	1207, Result status: Final
Ordering provider: Dronca, Roxana Filed by: Interface, Mc In Orm_Oru I 05/06/19 1207 Resulting lab: MAYO CLINIC JACKS Acknowledged by: Dronca, Roxana Components	Lab Generic 609301 SONVILLE CLINICAL LAB	Order status: Comp Collected by: 05/06,		
Component	Value	Reference Range	Flag	Lab
Source	Voided		-	JXC
Glucose	Negative	Negative mg/dL		JXC
Ketones	Negative	Negative	-	JXC
Hemoglobin, QL	Large	Negative	A !	JXC
Protein, U	30	Negative mg/dL	A!	JXC
Nitrite, U	Positive	Negative	A!	JXC
Nune, O				1110
Bilirubin	Negative	Negative	-	JXC
	Negative 1.016	Negative 1.002 - 1.030	=	JXC JXC
Bilirubin	Provide the second s			and the second s
Bilirubin Specific Gravity	1.016	1.002 - 1.030	-	JXC
Bilirubin Specific Gravity pH, U	1.016 5.0	1.002 - 1.030 5.0 - 8.0		JXC
Bilirubin Specific Gravity pH, U Urobilinogen	1.016 5.0 Normal	1.002 - 1.030 5.0 - 8.0 Normal	Ξ	JXC JXC JXC
Bilirubin Specific Gravity pH, U Urobilinogen Leukocyte Esterase White Blood Cells Comment: REFERENCE VALUE Male: 0-3	1.016 5.0 Normal Large	1.002 - 1.030 5.0 - 8.0 Normal Negative	 A! A!	JXC JXC JXC JXC
Bilirubin Specific Gravity pH, U Urobilinogen Leukocyte Esterase White Blood Cells Comment: REFERENCE VALUE Male: 0-3 Female: 0-10	1.016 5.0 Normal Large >182	1.002 - 1.030 5.0 - 8.0 Normal Negative /hpf	 A! A!	JXC JXC JXC JXC TXC
Bilirubin Specific Gravity pH, U Urobilinogen Leukocyte Esterase White Blood Cells Comment: REFERENCE VALUE Male: 0-3 Female: 0-10 Urine RBC	1.016 5.0 Normal Large >182 >182	1.002 - 1.030 5.0 - 8.0 Normal Negative /hpf 0 - 2 /hpf	 	JXC JXC JXC JXC JXC
Bilirubin Specific Gravity pH, U Urobilinogen Leukocyte Esterase White Blood Cells Comment: REFERENCE VALUE Male: 0-3 Female: 0-10 Urine RBC Bacteria	1.016 5.0 Normal Large >182 >182 >182 Present Present	1.002 - 1.030 5.0 - 8.0 Normal Negative /hpf 0 - 2 /hpf Not Seen	 A! A! A!	JXC JXC JXC JXC JXC

Testing Performed By


Lab - Abbreviation	Name	Director	Address	Valid Date Range
25 - JXC	MAYO CLINIC JACKSONVILLE CLINICAL LAB	Unknown	4500 San Pablo Rd Jacksonville FL 32224	10/08/18 1108 - 03/12/21 115





05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

(continued)			
Indications			
Pain Rectal [K62.89 (ICD-10-CM)] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2 (IC Mass Rectum [R19.09 (ICD-10-CM)]	CD-10-CM)]		
All Reviewers List			
Dronca, Roxana S, M.D. on 5/28/2019 18:38 Dronca, Roxana S, M.D. on 5/6/2019 18:21			
acterial Culture, Aerobic + Susc, Urine [2222487092935] (Final r	result)		
Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 0940 This order may be acted on in another encounter. Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - Quantity: 1 Instance released by: Pickett, Victoria R 5/6/2019 10:17 AM Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Bladder Lateral Wali (HCC) [C67,2] Mass Rectum [R19.09] Provider Details) Ordering provider: Dr Ordering mode: Stan Class: Lab Collect Lab status: Final resu	dard	Status: Complete
Provider	NPI		
Dronca, Roxana S, M.D. Questionnaire	1982657052		
Question	Answer		
Specimen Src:	Urine, Midstream	and some section in the local section of the local	
Indication: Region	Urine frequency, un Florida Region	gency, or dysuria	
Specimen Information			
ID Type Source		Collected By	
E006010852:2 Urine Urine, Mid Comment: Specimen Source Site: Urine Bacterial Culture, Aerobic + Susc, Urine [2222487092935] (Ab		05/06/19 1029	
Ordering provider: Dronca, Roxana S, M.D. 05/06/19 1017 Filed by: Interface, Mc In Orm_Oru Lab Generic 609301 05/08/19 1111 Resulting lab: MAYO CLINIC JACKSONVILLE CLINICAL LAB Acknowledged by: Dronca, Roxana S, M.D. on 05/28/19 1838	Order status: Comp Collected by: 05/06	leted	1, Result status: Final res
Components			
Component Value	Reference Range	Flag	Lab
Urine Culture Result: ESCHERICHIA COLI	-	A !	JXC



MAYO CLINIC

05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Labs (continued)

, >100,000 cfu/mL

Organism	Antibiotic	Sensitivity	Method
Escherichia coli	Ampicillin + Sulbactam	<=1/.5 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Ampicillin	<=8 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Aztreonam	<=4 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Ceftriaxone	<=1 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Ceftazidime	<=1 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Cefazolin	<=2 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Cefepime	<=2 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Cefuroxime-Sodium	<=4 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Nitrofurantoin	<=32 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Gentamicin	<=1 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Levofloxacin	<=0.25 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Piperacillin + Tazobactam	<=4 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Piperacillin	<=16 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Trimethoprim + Sulfamethoxazole	<=2/38 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Tetracycline	<=4 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Tigecycline	<=2 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)
Escherichia coli	Tobramycin	<=1 Susceptible	SUSCEPTIBILITY, MIC (MCG/ML)

Testing Performed By

Lab - Abbreviation	Name	Director	Address	Valid Date Range
25 - JXC	MAYO CLINIC JACKSONVILLE CLINICAL LAB	Unknown	4500 San Pablo Rd Jacksonville FL 32224	10/08/18 1108 - 03/12/21 1151

Indications

Pain Rectal [K62.89 (ICD-10-CM)] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2 (ICD-10-CM)] Mass Rectum [R19.09 (ICD-10-CM)]



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Labs (continued)

All Reviewers List

Dronca, Roxana S, M.D. on 5/28/2019 18:38

Medication List

Medication List

This report is for documentation purposes only. The patient should not follow medication instructions within. For accurate instructions regarding medications, the patient should instead consult their physician or after visit summary.

oratadine (CLARITIN) 10 mg tablet	
Discontinued by: Bowles, Desiree D, R.N. Instructions: Take 10 mg by mouth 5 (five) times a week. M-F	Discontinued on: 5/22/2019
Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
sosorbide mononitrate (IMDUR) 30 mg 24 hr tablet	
Instructions: Take 30 mg by mouth daily.	A COMPANY OF THE OWNER OF THE OWNER
Entered by: Ray, Amanda C	Entered on: 5/6/2019
multivit with min-folic acid (MEN'S MULTIVITAMIN GUMMIE	S) 200 mcg tablet,chewable
Instructions: Chew 200 mg daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
omeprazole (PriLOSEC) 40 mg DR capsule	
Discontinued by: Bowles, Desiree D, R.N. Instructions: Take 40 mg by mouth 2 (two) times a day.	Discontinued on: 5/22/2019
Entered by: Ray, Amanda C	Entered on: 5/6/2019
End date: 5/22/2019	Entered on: Job2013
inasteride (PROSCAR) 5 mg tablet	
Instructions: Take 5 mg by mouth daily.	Contraction of the second s
Entered by: Ray, Amanda C	Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA-3, I	PF,) 0.5-1-0.5 % dropperette
Instructions: Administer into both eyes 2 (two) times a day.	and the second se
Entered by: Ray, Amanda C	Entered on: 5/6/2019
ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable tabl	let
Instructions: Chew 500 mg daily.	NAMES IN A COMPANY OF THE OWNER
Entered by: Ray, Amanda C	Entered on: 5/6/2019
simvastatin (ZOCOR) 20 mg tablet	
simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime, Entered by: Ray, Amanda C	Entered on: 5/6/2019



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Medication List (continued)

amLODIPine (NORVASC) 5 mg tablet

Discontinued by: Bowles, Desiree D, R.N. Instructions: Take 5 mg by mouth daily. Entered by: Mathews, Carlyne P, R.N. End date: 5/22/2019 Discontinued on: 5/22/2019

Entered on: 5/7/2019 Informant: Self

Stopped in Visit

None



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida

Information			
ppointment Informa	tion		
LAB TEST BLOOD 5/6/2019 10:20 AM		Completed	
Time	Provider	Department	Length
10:20 AM	LAB BLOOD 01 JAMG	FLA LAB JAMG	10 mir
Referral Provider:	DRONCA, ROXANA S	Arrival Time: 10:17 AM	
History			
Made On:	5/6/2019 9:51 AM	By: Margol, Gabrielle H	ES
Checked In:	5/6/2019 10:17 AM	By: Pickett, Victoria R	ES
EOD Status:	5/10/2019 2:46 AM	By: Cadence,Batch Job	ES

Reason for Visit

Visit Diagnoses

- .
- Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder Lateral Wall [C67.2] ٠
- Pain Rectal [K62.89] ٠
- ٠ Mass Rectum [R19.09]

Clinical Notes

No documentation.

Imaging

No documentation.

Labs

Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 093 This order may be acted on in another encounter.	30	Status: Completed
Ordering user: Dronca, Roxana S, M.D. 05/06/19 0930 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - Quantity: 1 Instance released by: Pickett, Victoria R 5/6/2019 10:17 AM Diagnoses Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2]	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect Lab status: Final result	
Provider Details		
Provider	NPI	



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Dronca, Roxana S,	M.D.		1982657052		
Questionnaire					
Question			Answer		
Region			Florida Region		
Specimen Informa	tion				
ID	Туре	Source		Collected By	
E006010827:3	Blood	Blood, Ver	nous	05/06/19 1028	
CBC with Differen	tial, Blood [22224870	92931] (Abnormal)	Res	ulted: 05/06/19	1147, Result status: Final r
Ordering provider:	Dronca, Roxana S, M	.D. 05/06/19 1017	Order status: Comp		
	Mc In Orm_Oru Lab	Generic 609301	Collected by: 05/06		
05/06/19 1147		in Lotte Product			
		VILLE CLINICAL LAB			
Acknowledged by:	Dronca, Roxana S, M	.D. on 05/06/19 1821			
Components					
Component		Value	Reference Range	Flag	Lab
Leukocytes		5.2	3.4 - 9.6 x10(9)/L	-	JXC
Erythrocytes		3.10	4.35 - 5.65 x10(12)/L	L¥	JXC
Hemoglobin		9.9	13.2 - 16.6 g/dL	L×	JXC
Hematocrit		31.8	38.3 - 48.6 %	LY	JXC
MCV		102.6	78.2 - 97.9 fL	н^	JXC
MCH		31.9	25.4 - 32.7 pg	4	JXC
MCHC		31.1	32.1 - 35.6 g/dL	LY	JXC
RDW CV		15.2	11.8 - 14.5 %	H^	JXC
RDW SD		54.8	35.1 - 43.9 fL	H^	JXC
Platelet Count		54	135 - 317 x10(9)/L	LY	JXC
Mean Platelet	Volume	10.4	7.6 - 10.8 fL	-	JXC
Neutrophils %		84.1	50.0 - 75.0 %	н^	JXC
Immature Gran	ulocytes %	0.8	0.0 - 3.0 %	-	JXC
Lymphocytes	and particular and the second s	11.2	18.0 - 42.0 %	LY	JXC
Monocytes %		1.2	2.0 - 11.0 %	LY	JXC
Eosinophils %		2.3	1.0 - 3.0 %	-	JXC
Basophils %		0.4	0.0 - 2.0 %	-	JXC
Neutrophils		4.38	1.56 - 6.45	-	JXC
		1796.51	x10(9)/L		
Lymphocytes		0.58	0.95 - 3.07	LY	JXC
			x10(9)/L		
		0.06	0.26 - 0.81	LY	JXC
Monocytes					
			x10(9)/L		1495
Monocytes Eosinophils Basophils		0.12	x10(9)/L 0.03 - 0.48 x10(9)/L 0.0 - 0.1 x10(9)/L	-	JXC



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Testing Performed B	Зу				
Lab - Abbreviatio	on Name	Director	Address		Valid Date Range
25 - JXC	MAYO CLINIC JACKSONVILLE CLINICAL LAB	Unknown	4500 San Pa Jacksonville		10/08/18 1108 - 03/12/21 115
Indications					
Pain Arm Left [M7 Malignant Neoplas	9.602 (ICD-10-CM)] sm Of Bladder Lateral Wall	(HCC) [C67.2 (ICC	D-10-CM)]		
All Reviewers List					
Dronca, Roxana S	6, M.D. on 5/6/2019 18:21				
Electronically signed by: This order may be acted Ordering user: Dronca, R Authorized by: Dronca, R Frequency: Routine 05/0 Quantity: 1 Instance released by: Pic Diagnoses		on 05/06/19 0930 930	Ordering provider: Dr Ordering mode: Stan Class: Lab Collect Lab status: Final resu	dard	Status: Comple
Pain Arm Left [M79.602] Malignant Neoplasm Of E Provider Details Provider	Bladder Lateral Wall (HCC)) [C67.2]	NPI		
Alignant Neoplasm Of E Provider Details) [C67.2]	NPI 1982657052		
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M) [C67.2]		_	
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire) [C67.2]			
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question) [C67.2]	1982657052 Answer		
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire) [C67.2]	1982657052		
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question	1.D.) [C67.2]	1982657052 Answer		
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T	1.D.) [C67.2]	1982657052 Answer	Collected	Ву
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T	1.D.		1982657052 Answer Florida Region	Collected 05/06/19 10	
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E	1.D. on	Source Blood, Veno	1982657052 Answer Florida Region	05/06/19 10	028
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E Comprehensive Meta Ordering provider: Dr Filed by: Interface, M 05/06/19 1126 Resulting lab: MAYO	1.D. on Type Blood	Source Blood, Veno 932] (Abnormal) 06/19 1017 : 609301 CLINICAL LAB	1982657052 Answer Florida Region	05/06/19 10 ulted: 05/06/ leted	
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E Comprehensive Meta Ordering provider: Dr Filed by: Interface, M- 05/06/19 1126 Resulting lab: MAYO Acknowledged by: Dr	A.D. A.D. Type Blood abolic Panel [2222487092 ronca, Roxana S, M.D. 05/ c In Orm_Oru Lab Generic CLINIC JACKSONVILLE C	Source Blood, Veno 932] (Abnormal) 06/19 1017 : 609301 CLINICAL LAB 05/06/19 1821	1982657052 Answer Florida Region ous Resu Order status: Comp	05/06/19 10 ulted: 05/06/ leted	028
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E Comprehensive Meta Ordering provider: Dr Filed by: Interface, Meta Ofdering provider: Dr Filed by: Interface, Meta 05/06/19 1126 Resulting lab: MAYO Acknowledged by: Dr Components Component	A.D. A.D. Type Blood abolic Panel [2222487092 ronca, Roxana S, M.D. 05/ c In Orm_Oru Lab Generic CLINIC JACKSONVILLE C	Source Blood, Veno 932] (Abnormal) 06/19 1017 609301 CLINICAL LAB 05/06/19 1821 Value	1982657052 Answer Florida Region Nus Order status: Comp Collected by: 05/06/ Reference Range	05/06/19 1(ulted: 05/06/ leted 19 1028	028 /19 1126, Result status: Final re Lab
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E Comprehensive Meta Ordering provider: Dr Filed by: Interface, Meta Ofdering provider: Dr Filed by: Interface, Meta Ofdering lab: MAYO Acknowledged by: Dr Components Component Potassium, P	A.D. A.D. Type Blood abolic Panel [2222487092 ronca, Roxana S, M.D. 05/ c In Orm_Oru Lab Generic CLINIC JACKSONVILLE C	Source Blood, Veno 932] (Abnormal) 06/19 1017 609301 CLINICAL LAB 05/06/19 1821 Value 5.0	1982657052 Answer Florida Region nus Corder status: Comp Collected by: 05/06/ Reference Range 3.6 - 5.2 mmol/L	05/06/19 1(ulted: 05/06/ leted 19 1028	028 /19 1126, Result status: Final re
Malignant Neoplasm Of E Provider Details Provider Dronca, Roxana S, M Questionnaire Question Region Specimen Informatio ID T E006010827:4 E Comprehensive Meta Ordering provider: Dr Filed by: Interface, Meta Ofdering provider: Dr Filed by: Interface, Meta Ofdering lab: MAYO Acknowledged by: Dr Components Component	A.D. A.D. Type Blood abolic Panel [2222487092 ronca, Roxana S, M.D. 05/ c In Orm_Oru Lab Generic CLINIC JACKSONVILLE C	Source Blood, Veno 932] (Abnormal) 06/19 1017 609301 CLINICAL LAB 05/06/19 1821 Value	1982657052 Answer Florida Region Nus Order status: Comp Collected by: 05/06/ Reference Range	05/06/19 10 ulted: 05/06/ leted 19 1028 Flag	028 /19 1126, Result status: Final re Lab



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Bicarbonate, P		26	22 - 29 mmol/L	-	JXC
Anion Gap, P		8	7 - 15	1	JXC
BUN (Blood Urea Nitro	gen), P	30	8 - 24 mg/dL	H^	JXC
Creatinine, P	90.00	1.92	0.74 - 1.35 mg/dL	H^	JXC
eGFR-Black/African Ar	nerican	39	>=60 mL/min/BSA	LY	JXC
Comment:				-	
ADDITIONAL INF Estimated GFR calcu equation.	ORMATION ulated using the 2009 C	CKD_EPI creatin	ine		
eGFR Non-Black/Africa Comment:	an American	34	>=60 mL/min/BSA	L¥	JXC
ADDITIONAL INF Estimated GFR calcu equation.	ORMATION ulated using the 2009 C	CKD_EPI creatin	ine		
Calcium, Total, P		8.8	8.8 - 10.2 mg/dL	4	JXC
Glucose, P		108	70 - 140 mg/dL	-	JXC
Protein, Total, P			6.3 - 7.9 g/dL	-	JXC
Albumin, P		6.5 3.9	3.5 - 5.0 g/dL		JXC
Aspartate Aminotransf	erase (AST), P	55	8 - 48 U/L	H*	JXC
Alkaline Phosphatase,		73	40 - 129 U/L	-	JXC
Alanine Aminotransfer		52	7 - 55 U/L	-	JXC
Bilirubin, Total, P		1.2	<=1.2 mg/dL	1	JXC
Testing Performed By Lab - Abbreviation 25 - JXC	Name MAYO CLINIC JACKSONVILLE CLINICAL LAB	Director Unknown	Address 4500 San Jacksonvi	Pablo Rd lle FL 32224	Valid Date Range 10/08/18 1108 - 03/12/21 115
All Reviewers List	Of Bladder Lateral Wal	II (HCC) [C67.2)	(ICD-10-CM)]		
Pain Arm Left [M79.6 Malignant Neoplasm All Reviewers List	Of Bladder Lateral Wal I.D. on 5/6/2019 18:21 Discontinued)				

Discontinued by: Interface, Mc In Orm_Oru Lab Generic 609301 05/06/19 1017 [Order Cancelled by Lab (Cancelled due to duplicate test on this order)]



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Diagnoses Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder L Provider Details Provider Dronca, Roxana S, M.D. Questionnaire	1	NPI 1982657052	
Provider Details Provider Dronca, Roxana S, M.D.	1		
Dronca, Roxana S, M.D.			
Dronca, Roxana S, M.D.			
		1987057057	
Questionnaire			
Question		Answer	
Region Florida Region			
Specimen Information			
ID Type	Source	Collected By	
E006010827:1 Blood	Blood, Venous		
Indications			
Pain Arm Left [M79.602 (IC	CD-10-CM)]		
Malignant Neoplasm Of Bla	adder Lateral Wall (HCC) [C67.2 (ICD-1	I-10-CM)]	
Quantity: 1 Discontinued by: Interface, Mc In on this order)] Diagnoses Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder L	Orm_Oru Lab Generic 609301 05/06/1	Instance released by: Pickett, Victoria R 5/6/2019 10:17 AM /19 1017 [Order Cancelled by Lab (Cancelled due to duplicate te	
Provider Details	, ,		
Provider	1	NPI	
Dronca, Roxana S, M.D.	1	1982657052	
Questionnaire			
Question		Answer	
Region		Florida Region	
Specimen Information			
	Source	Collected By	
ID Туре			
	Blood, Venous	us —	
ID Type E006010827:2 Blood	Blood, Venous	US —	
ID Type E006010827:2 Blood Indications		us —	
ID Type E006010827:2 Blood Indications Pain Arm Left [M79.602 (IC			



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

s (continued)				
Ordering user: Dron Authorized by: Dron Frequency: Routine Quantity: 1 Discontinued by: Intr on this order)] Diagnoses Pain Rectal [K62.89]	05/06/19 - erface, Mc In Orm_Oru Lab Generic 60 I Of Bladder Lateral Wall (HCC) [C67.2	Ordering provider Ordering mode: S Class: Lab Collec Instance released 9301 05/06/19 1017 [Order	ot d by: Pickett, Victoria B 5/6/	Status: Discontinued 2019 10:17 AM ed due to duplicate test
Provider		NPI		
Dronca, Roxana	S, M.D.	1982657052		
Questionnaire				
Question		Answer		
Region		Florida Region		
ID E006010827:5	Туре 5	ource llood, Venous	Collected By	
Malignant Neo	62.89 (ICD-10-CM)] oplasm Of Bladder Lateral Wall (HCC) [R19.09 (ICD-10-CM)]	[C67.2 (ICD-10-CM)]		
ication List				
Medication List	The second second	and the second second		
This report is for of For accurate instr Active at the End	documentation purposes only. The p uctions regarding medications, the I of Visit	patient should not follow m patient should instead con	nedication instructions wi Isult their physician or af	thin. ter visit summary.
Ioratadine (Cl	LARITIN) 10 mg tablet			
Instructions:	by: Bowles, Desiree D, R.N. Take 10 mg by mouth 5 (five) times a v Ray, Amanda C 2/2019	veek. M-F	Discontinued on: 5/22/2019 F Entered on: 5/6/2019	
isosorbide m	ononitrate (IMDUR) 30 mg 24 hr tabl	et		
Instructions:				



05/06/2019 - Appointment in Department of Laboratory Medicine and Pathology, Mangurian Building, in Jacksonville, Florida (continued)

Medication List (continued) multivit with min-folic acid (MEN'S MULTIVITAMIN GUMMIES) 200 mcg tablet, chewable Instructions: Chew 200 mg daily. Entered by: Ray, Amanda C Entered on: 5/6/2019 omeprazole (PriLOSEC) 40 mg DR capsule Discontinued by: Bowles, Desiree D, R.N. Discontinued on: 5/22/2019 Instructions: Take 40 mg by mouth 2 (two) times a day. Entered by: Ray, Amanda C Entered on: 5/6/2019 End date: 5/22/2019 finasteride (PROSCAR) 5 mg tablet Instructions: Take 5 mg by mouth daily. Entered by: Ray, Amanda C Entered on: 5/6/2019 carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA-3, PF,) 0.5-1-0.5 % dropperette Instructions: Administer into both eyes 2 (two) times a day. Entered by: Ray, Amanda C Entered on: 5/6/2019 ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable tablet Instructions: Chew 500 mg daily. Entered by: Ray, Amanda C Entered on: 5/6/2019 simvastatin (ZOCOR) 20 mg tablet Instructions: Take 20 mg by mouth at bedtime. Entered by: Ray, Amanda C Entered on: 5/6/2019 amLODIPine (NORVASC) 5 mg tablet Discontinued by: Bowles, Desiree D, R.N. Discontinued on: 5/22/2019 Instructions: Take 5 mg by mouth daily. Entered by: Mathews, Carlyne P, R.N. Entered on: 5/7/2019 End date: 5/22/2019 Informant: Self Stopped in Visit

None



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida

Visit Information

the second			
Encounter Provider	Authorizing F		
Dronca, Roxana S, M.D.	Dronca, Roxana S, M.D.		
Department			
Name		Phone	Fax
Division of Hematology and Medical Oncology in Jacksonville, Florida	4500 SAN PABLO RD S Jacksonville FL 32224-1865	904-953-2000	904-953-2315
Level of Service			
Level of Service			
PR VISIT NEW PATIENT LEVEL 5			
eason for Visit			
Visit Diagnoses			
Pain Arm Left (primary) [M79.602]			
Pain Rectal [K62.89]			
 Malignant Neoplasm Of Bladder Lat Mass Rectum [R19.09] 	eral Wall [C67.2]		
· Mass Recton [R13.03]			
inical Notes			
inical Notes H&P			
H&P	/6/2019 9:00 AM		
	Service: ONC Hematology and On Encounter Date: 5/6/2019	cology Author Ty Status: S	pe: Physician gned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P	Service: ONC Hematology and On Encounter Date: 5/6/2019		pe: Physician igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN	Service: ONC Hematology and On Encounter Date: 5/6/2019		pe: Physician gned
H&P <u>H&P by Dronca, Roxana S, M.D. at 5</u> Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN	Service: ONC Hematology and On Encounter Date: 5/6/2019		pe: Physician gned
H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file.	Service: ONC Hematology and On Encounter Date: 5/6/2019		rpe: Physician igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. DCAL ONCOLOGIST	Service: ONC Hematology and On Encounter Date: 5/6/2019		rpe: Physician igned
H&P <u>H&P by Dronca, Roxana S, M.D. at 5</u> Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN	Service: ONC Hematology and On Encounter Date: 5/6/2019		pe: Physician gned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. OCAL ONCOLOGIST o care team member to display	Service: ONC Hematology and On Encounter Date: 5/6/2019		rpe: Physician igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. OCAL ONCOLOGIST	Service: ONC Hematology and On Encounter Date: 5/6/2019		pe: Physician gned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. OCAL ONCOLOGIST o care team member to display	Service: ONC Hematology and On Encounter Date: 5/6/2019 hysician)		rpe: Physician igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. DCAL ONCOLOGIST o care team member to display ATIENT IS SELF-REFERRED HIEF COMPLAINT / REASON FOR	Service: ONC Hematology and On Encounter Date: 5/6/2019 hysician)	Status: S	igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. DCAL ONCOLOGIST o care team member to display ATIENT IS SELF-REFERRED HIEF COMPLAINT / REASON FOR utpatient Kermit William Coles is a 7	Service: ONC Hematology and On Encounter Date: 5/6/2019 hysician)	Status: S	igned
H&P H&P by Dronca, Roxana S, M.D. at 5 Author: Dronca, Roxana S, M.D. Filed: 5/15/2019 3:18 PM Editor: Dronca, Roxana S, M.D. (P RIMARY CARE PHYSICIAN o primary care provider on file. OCAL ONCOLOGIST o care team member to display ATIENT IS SELF-REFERRED HIEF COMPLAINT / REASON FOR	Service: ONC Hematology and On Encounter Date: 5/6/2019 hysician)	Status: S	igned

HISTORY OF PRESENT ILLNESS

Oncology History

Mr. Coles is a very pleasant 72-year-old gentleman whose oncologic history summarized below:



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Clinical Notes (continued)

1. The patient had a long history of symptoms suggestive of combination of bladder outlet obstruction with BPH and overactive bladder confirmed with urodynamic studies. He was treated conservatively by Urology. Was evaluated with cystoscopy in October of 2018 and again in December of 2018.

2. 12/28/2018 by manual exam suggested a mass effect in the left lower quadrant per Urology notes, Botox injection of the bladder could not be done on the left side of the bladder, also the left side appeared pale. Further imaging was recommended.

3. 01/03/2019 the patient underwent MRI of the pelvis consistent with wall thickening on the left side of the bladder up to 1.4 cm thickness, extending to the level of the left UVJ. Bilateral distal ureters moderately dilated. No distinct lymphadenopathy.

4. 02/14/2019 the patient presented to Emergency Department at Memorial Hospital with constipation. Creatinine was found to be 3.3. Per patient he underwent sigmoidoscopy. Biopsy of a rectal mass showed a long gated course of fibromuscular tissue with muscle propria with infiltrating urothelial carcinoma. Urinary bladder tumor biopsies showing 2 fragments of a highgrade urothelial carcinoma with tumor invasion involving submucosal connective tissue and the muscularis propria, focally.

5. The patient was evaluated by Oncology who recommended neoadjuvant chemotherapy with gemcitabine and Taxol 3/4 weeks, as the patient was unable to take cisplatin due to elevated creatinine.

6. 03/01/2019 ultrasound showed moderate to severe hydronephrosis bilaterally. The patient underwent bilateral nephrostomy tube placement on March 5, 2019.

7. 03/08/2019 started gemcitabine and Taxol. Creatinine decreased to 2.2. Course of chemotherapy was complicated by neutropenia. On the 1st cycle he had treatment every other week. Was initiated apparently on GM-CSF twice a week. Cycle 2 was able to complete 3 treatments, last chemotherapy treatment was Friday May 3, 2019. At that time per patient he was only given half a dose because he was found to be thrombocytopenic.

Of note the patient's course was also complicated by E coli urinary infection which was treated with Keflex.

Also tumor was tested for PD L1 and per notes PD L1 expression is 0%.



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Clinical Notes (continued)

The patient's past medical history is significant for coronary artery disease/coronary spasm, GERD, hemorrhoids, BPH, and cataracts.

Malignant Neoplasm Of Bladder Lateral Wall (HCC)

INTERVAL HISTORY:

Mr. Coles is here today for a 2nd opinion consultation. As outlined in his oncological history, he is currently undergoing chemotherapy with gemcitabine and Taxol. His last dose was last Friday May 3rd. He still main concerns right now relate to left arm and forearm pain swelling and hardening, since the last treatment. Also continues to have rectal discomfort, he defines this mostly as a burning sensation in the rectum. He is able to have bowel movements, however intermittently these are very small in caliber. For the last couple of days he has been having liquid stools which he attributes to chemotherapy. Denies any tenesmus, no blood in the stools. He also has intermittent right lower quadrant pain which usually is relieved with bowel movements. His appetite is maintained, weight has been stable recently, denies any nausea or vomiting. He has occasional night sweats. He does most normal urination patterns recently, has noticed that the tubes are draining very little in the last few days to a couple of weeks. He does have tenderness at the site of both nephrostomy tubes. Denies any blood in the urine. No fevers or chills. No shortness of breath, cough, chest pain. Otherwise the review of systems is fairly unremarkable.

ALLERGY

Allergies		
Allergen	Reactions	
 Triple Antibiotic [Neomycin-Bacitracnzn- Polymyxnb] 	Other (see comments)	
Causes area to become raw		
PAST MEDICAL HISTORY		
Past Medical History:		
Diagnosis		Date
 BenignProstatic Hyperplasia Localized 		2006
Cataract		11/3/2015 &
		02/14/2017
 Coronary Artery Disease (Unspecified) 		02/01/2007
 Gastroesophageal Reflux Disease NOS 		2009
 Hyperlipidemia 		02/01/2007
 Malignant Neoplasm Unspecified (HCC) Bladder cancer 		03/2019
Polyp Colon		12/2018

PAST SURGICAL HISTORY Past Surgical History:

12/30/2021 3:52 PM EST

User: IDMPROD20202342Release ID: 162663955



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Procedure	Laterality	Date	
APPENDECTOMY	100 M	1959	
 OTHER SURGICAL HISTORY 		1963	
Hemorrhoid surgery		Constraint and Constr	

MEDICATIONS

Current Outpatient Prescriptions:

- · ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable tablet, Chew 500 mg daily., Disp: , Rfl:
- carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA-3, PF,) 0.5-1-0.5 % dropperette, Administer into both eyes 2 (two) times a day., Disp:, Rfl:
- · finasteride (PROSCAR) 5 mg tablet, Take 5 mg by mouth daily., Disp: , Rfl:
- · isosorbide mononitrate (IMDUR) 30 mg 24 hr tablet, Take 30 mg by mouth daily., Disp: , Rfl:
- · loratadine (CLARITIN) 10 mg tablet, Take 10 mg by mouth 5 (five) times a week. M-F, Disp: , Rfl:
- multivit with min-folic acid (MEN'S MULTIVITAMIN GUMMIES) 200 mcg tablet, chewable, Chew 200 mg daily., Disp:
- , Rfl:

· omeprazole (PriLOSEC) 40 mg DR capsule, Take 40 mg by mouth 2 (two) times a day., Disp: , Rfl:

 polyethylene glycol-electrolytes (GoLYTELY) 236-22.74-6.74 -5.86 gram solution, Take 50% of prep night before by 10 pm and 50% of prep following morning starting at 0500 and finish before appointment, as directed., Disp: 4000 mL, Rfl: 0

· simvastatin (ZOCOR) 20 mg tablet, Take 20 mg by mouth daily., Disp: , Rfl:

SOCIAL		
Social History		
Substance Use Topics		
 Smoking status: 	Former Smoker	
Years:	42.00	
Types:	Cigarettes	
Start date:	10/1/1965	
Quit date:	2/1/2007	
 Smokeless tobacco: 	Never Used	
Alcohol use	No	
FAMILY HISTORY		
Family History		
Problem	Relation	Age of Onset
 Coronary artery disease Heart attack at 80 	Father	
Stroke 84	Father	
 Coronary artery disease Heart attack at 91 	Mother	
 Coronary artery disease 	Maternal Grandfather	
12/30/2021 3:52 PM EST	User: IDMPROD20202342Release ID: 162663955	Page



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Clinical Notes	(continued))
-----------------------	-------------	---

Heart attack at 50	
Diabetes 60	Father's Brother
Asthma 50	Paternal Grandfather
• ADD 7	Son

REVIEW OF SYSTEMS

A complete 14 system review was performed and negative unless otherwise stated below or in the HPI.

PHYSICAL EXAMINATION

ECOG: 0

Vitals: Blood pressure 107/72, pulse 106, temperature 37.1 °C, temperature source Oral, height 180.3 cm, weight 81 kg, SpO2 98 %. Body mass index is 24.9 kg/m².

General appearance: No acute distress

Psychiatric: Appropriate affect. Oriented X 3.

Eyes: PERRLA. Conjunctiva normal.

Ears/nose/throat/mouth: Oropharynx-Mucous membranes moist. Normal dentition. No oral lesions. No pharyngeal exudates.

Cardiovascular: Auscultation- S1/S2; RRR, no murmurs/rubs/gallops. Left arm has evidence of slight erythema, is slightly hard to palpation, possibly suggestive of a superficial thrombophlebitis. Lower extremities with trace pitting edema bilaterally.

Pulmonary: Auscultation-CTA bilaterally, no wheezes, crackles, or rhonchi. Normal respiratory effort.

Abdomen: Soft, mildly tender to palpation RLQ, no rebound or guarding, non-distended. No hepasplenomegaly or masses appreciated. Bilateral nephrostomy tubes in place, no surrounding erythema.

Musculoskeletal: Gait- normal. Digits- no clubbing. No joint swelling or erythema.

Dermatologic: Palpation-Skin warm. Inspection-No visible rashes.

Lymphatic: No cervical, supraclavicular, axillary, or inguinal lymphadenopathy.

Neurologic: CN2-12 grossly intact. No focal neurological deficits appreciated.

DIAGNOSTICS:

I reviewed the imaging studies and agree with the interpretation as recorded. I reviewed the pertinent laboratory, pathology and diagnostic data.

ASSESSMENT/PLAN:

Mr. Kermit William Coles is a very pleasant 72 y.o.male with a history of bladder tumor, with possible invasion in the rectum



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Clinical Notes (continued)

1. Bladder cancer within invasion and muscularis propria, as well as possible rectal invasion

I reviewed Mr.Coles outside medical records in detail as well as outside imaging. The patient is currently undergoing neoadjuvant chemotherapy, however this does not involve cisplatin given that he had renal insufficiency at the time. He has been having difficulty tolerating treatment. Also he has increasing rectal symptoms. Therefore I believe that he needs to undergo restaging given that his already had a couple of cycles of therapy. The patient would like a 2nd opinion surgical consultation at Mayo Clinic, as at home was initially thought that he may need to have a more extensive surgery involving removal of the rectum, but the plan was later changed to cystectomy alone.

Therefore, I will request an MRI of the abdomen and pelvis. Will schedule also a sigmoidoscopy for evaluation of rectal invasion. I will have him see one of our colleagues in colorectal surgery, as well as Dr. Young in Urology.

2. Chronic renal insufficiency status post bilateral nephrostomy tubes

Will recheck blood test today, will also schedule an appointment in IR to check his to his for obstruction.

3. Thrombocytopenia

Patient was found to be thrombocytopenic last Friday prior to administration of chemotherapy. They worried that his counts may be even lower today. Will repeat a CBC with differential.

4. Left arm pain, swelling and erythema

Will schedule an ultrasound to rule out superficial thrombophlebitis or DVT.

PATIENT ROS

Patient's noted ROS was reviewed and pertinent acute concerns were discussed and addressed as appropriate.

PATIENT EDUCATION

Ready to learn, no apparent learning barriers were identified; learning preferences include listening. Explained diagnosis and treatment plan; patient expressed understanding of the content.

ADMINISTRATIVE BILLING

I personally spent over half of a total 60 minutes face to face with the patient in counseling and discussion and/or coordination of care as described above.

Roxana Dronca, M.D. Associate Professor of Oncology Mayo Clinic Florida 4500 San Pablo Road | Jacksonville, FL 32224 Secretary: 904-953-2607 | Fax: 904-953-2315 Email: <u>dronca.roxana@mayo.edu</u> www.mayoclinic.org



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Clinical Notes (continued)

Electronically Signed by Dronca, Roxana S, M.D. on 5/15/2019 3:18 PM

Other Orders

dications		
polyethylene glycol-electrolytes (GoLYTELY) 236-22.74-6.	74 -5.86 gram solution [2222487049942] (Expired)	
Electronically signed by: Dronca, Roxana S, M.D. on 05/06/ Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - 05/07/19 2359 Provider Details		Status: Expired
Provider	NPI	
Dronca, Roxana S, M.D.	1982657052	

Admin instructions; Take 50% of prep night before by 10 pm and 50% of prep following morning starting at 0500 and finish before appointment, as directed.

Imaging

aging		
MR Abdomen Pelvis Urogram without and with IV Contrast [22	22487049940] (Completed)	
Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 09 Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: RAD - Routine (most inpatients and all outpatients) 05/06/19 - Quantity: 1	40 Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed Indications comment: bladder cancer with pe	Status: Complete
	rectal mass	in and possible
Diagnoses		
Pain Rectal [K62,89]		
Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2] Mass Rectum [R19.09]		
Provider Details		
Provider	NPI	
Dronca, Roxana S, M.D.	1982657052	
Questionnaire		
Question	Answer	
Clinical question to be answered	bladder cancer with pelvi and possible recta	al mass
Sedation Preference (Radiology may change)	No Sedation	
Contrast or non-Contrast use will ultimately be at the discretion of Radiology unless specified:	l agree	



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)


Region	Florida Region
MRI SAFETY High Risk Device Review: Does the patient have or ever had one of these devices?	No, the patient does NOT have nor has ever had any of these high risk devices
Indications	
Pain Rectal [K62.89 (ICD-10-CM)] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2 Mass Rectum [R19.09 (ICD-10-CM)]	(ICD-10-CM)]
US Upper Extremity Veins Left [2222487049939] (Completed)	
Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 0	930 Status: Complete
Ordering user: Dronca, Roxana S, M.D. 05/06/19 0930 Authorized by: Dronca, Roxana S, M.D. Frequency: RAD - Routine (most inpatients and all outpatients) 05/06/19 - Quantity: 1 Diagnoses Pain Arm Left [M79.602] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2]	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed
Provider Details	
Provider	NPI
Dronca, Roxana S, M.D.	1982657052
Questionnaire	
Question	Answer
Clinical question to be answered	left arm pain and swelling
Region:	Florida Region
Indications	
Pain Arm Left [M79.602 (ICD-10-CM)] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2	(ICD-10-CM)]
cedural Imaging	
URO Cystoscopy (general) [2222487049945] (Discontinued)	
	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed Discontinued by: Cockerill, Katherine J, M.D. 06/21/19 1424
URO Cystoscopy (general) [2222487049945] (Discontinued) Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 09 Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 -	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed
URO Cystoscopy (general) [2222487049945] (Discontinued) Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 09 Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2]	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed Discontinued by: Cockerill, Katherine J, M.D. 06/21/19 1424
URO Cystoscopy (general) [2222487049945] (Discontinued) Electronically signed by: Dronca, Roxana S, M.D. on 05/06/19 09 Ordering user: Dronca, Roxana S, M.D. 05/06/19 0940 Authorized by: Dronca, Roxana S, M.D. Frequency: Routine 05/06/19 - Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Bladder Lateral Wall (HCC) [C67.2] Mass Rectum [R19.09]	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Ancillary Performed Discontinued by: Cockerill, Katherine J, M.D. 06/21/19 1424



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Imaging (continued)

Questio	n	Answer	
Region		Florida Region	
Reason	for procedure	bladder cancer currently undergoing	neo-adjuvant chemo
Indicatio	ns		
Maligr	Rectal [K62.89 (ICD-10-CM)] hant Neoplasm Of Bladder La Rectum [R19.09 (ICD-10-CN	teral Wall (HCC) [C67.2 (ICD-10-CM)]]	
ripaluele with	Microscopic: Urino, Clean	Catch [2222487049944] (Completed)	
Ordering user: Authorized by: Frequency: Roi Quantity: 1 Diagnoses Pain Rectal [K6	plasm Of Bladder Lateral Wa	6/19 0940 Ordering provider: Dronca, Roxana S, Ordering mode: Standard Class: Lab Collect	Status: Complete M.D.
Provider De			
Provider		NPI	
Questionna	xana S, M.D. ire	1982657052	
Question		Answer	
Region: Specimen li	nformation	Florida Region	
ID	Туре	Source Collected By	
-	Urine	Urine, Clean Catch —	
Malignar Mass Re	ectum [R19.09 (ICD-10-CM)]	al Wall (HCC) [C67.2 (ICD-10-CM)] 222487049946] (Completed)	
Ordering user:	igned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/0 Dronca, Roxana S, M.D. vine, 05/06/19		Status: Complete , M.D.
Authorized by: Frequency: Roi Quantity: 1			





05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Pain Rectal [K6 Malignant Neor	52.89] blasm Of Bladder Lateral Wa	III (HCC) [C67.2]		
Mass Rectum [R19.09]	(1.00) [00) [2]		
Provider De	tails			
Provider		NPI		
Dronca, Ro.	xana S, M.D.	198	2657052	
Questionna	ire			
Question		Ans	wer	
Specimen S	Src:		e, Midstream	
Indication:		Urin	e frequency, urgency, or dysuria	
Region		Flor	ida Region	
Specimen Ir	nformation			
ID	Туре	Source	Collected By	
-	Urine	Urine, Midstream	-	
Indications				
Mass Re Ibumin [22224 Electronically si	t Neoplasm Of Bladder Late ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S	5, M.D. оп 05/06/19 0930		Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [M Alalignant Neop	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] lasm Of Bladder Lateral Wa	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] lasm Of Bladder Lateral Wa	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2]	ing provider: Dronca, Roxana S, M.D. ing mode: Standard	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] Ilasm Of Bladder Lateral Wa tails	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] NPI	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] lasm Of Bladder Lateral Wa	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] NPI	ing provider: Dronca, Roxana S, M.D. ing mode: Standard	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] M79.602] M79.602] kana S, M.D.	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] NPI	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider De Dronca, Ros Questionnai Question	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] M79.602] M79.602] kana S, M.D.	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198:	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider De Dronca, Ros Questionnai	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. utine 05/06/19 – M79.602] M79.602] M79.602] kana S, M.D.	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198:	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect 2657052	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider De Dronca, Ros Questionnai Question	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ 06/19 - M79.602] Ilasm Of Bladder Lateral Wa tails xana S, M.D. ire	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198:	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect 2657052 wer	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [Malignant Neop Provider De Provider De Provider De Dronca, Ros Questionnal Question Region	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ 06/19 - M79.602] Ilasm Of Bladder Lateral Wa tails xana S, M.D. ire	5, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198:	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect 2657052 wer da Region	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [M Alignant Neop Provider De Provider De Provider De Dronca, Rou Questionnal Question Region	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ 05/06/19 - M79.602] Ilasm Of Bladder Lateral Wa tails kana S, M.D. Ire	S, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198: Ans Flor	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect 2657052 wer	Status: Complet
Mass Re Ibumin [22224 Electronically si Ordering user: I Authorized by: I Frequency: Rou Quantity: 1 Diagnoses Pain Arm Left [M Alignant Neop Provider De Provider De Provider De Dronca, Rou Questionnal Question Region	ctum [R19.09 (ICD-10-CM)] 86982160] (Completed) gned by: Dronca, Roxana S Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ Dronca, Roxana S, M.D. 05/ 079.602] Ilasm Of Bladder Lateral Wa tails xana S, M.D. Ire Iformation Type	S, M.D. on 05/06/19 0930 06/19 0930 Order Order Class II (HCC) [C67.2] <u>NPI</u> 198: <u>Ans</u> Flor Source	ing provider: Dronca, Roxana S, M.D. ing mode: Standard : Lab Collect 2657052 wer da Region	Status: Complet



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Labs (continued)

IBy
Ву
Status: Complete ana S, M.D.
By
1 By



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Malignant Neopla Comprehensive Metab Electronically signed by Ordering user: Dronca,	79.602 (ICD-10-CM)] asm Of Bladder Lateral Wal polic Panel [222248698210	I (HCC) [C67.2 (ICC	and share	
Electronically signed by Ordering user: Dronca,	olic Panel [222248698210)-10-CM)]	
Ordering user: Dronca,		63] (Completed)		
Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Arm Left [M79.603 Malignant Neoplasm O Provider Details	5/06/19 -	0930	Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect	Status: Complete
Provider			NPI	
Dronca, Roxana S,	. M.D.		1982657052	
Questionnaire				
Question			Answer	
Region			Florida Region	
Specimen Informat	tion			
ID	Туре		8 H (115	
		Source	Collected By	
Indications Pain Arm Left [M	Blood	Source Blood, Vend	Collected By	
Pain Arm Left [M Malignant Neopl	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa	Blood, Vend	DUS —	
Pain Arm Left [M Malignant Neople Electronically signed by Ordering user: Dronca, Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm O Mass Rectum [R19.09]	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa ated GFR [2222487049948 y: Dronca, Roxana S, M.D Roxana S, M.D. 05/06/19 Roxana S, M.D. 5/06/19 - f Bladder Lateral Wall (HCG	Blood, Vend II (HCC) [C67.2 (IC (Completed) on 05/06/19 0940 0940	DUS —	Status: Complete
Pain Arm Left [M Malignant Neople Electronically signed by Ordering user: Dronca, Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Mass Rectum [R19.09] Provider Details	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa ated GFR [2222487049948 y: Dronca, Roxana S, M.D Roxana S, M.D. 05/06/19 Roxana S, M.D. 5/06/19 - f Bladder Lateral Wall (HCG	Blood, Vend II (HCC) [C67.2 (IC (Completed) on 05/06/19 0940 0940	D-10-CM)] Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect	Status: Complete
Pain Arm Left [M Malignant Neople Creatinine with Estima Electronically signed by Ordering user: Dronca, Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Mass Rectum [R19.09] Provider Details Provider	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa ated GFR [2222487049948 y: Dronca, Roxana S, M.D Roxana S, M.D. 05/06/19 Roxana S, M.D. 5/06/19 - f Bladder Lateral Wall (HCG	Blood, Vend II (HCC) [C67.2 (IC (Completed) on 05/06/19 0940 0940	D-10-CM)] Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect	Status: Complete
Pain Arm Left [M Malignant Neople Ereatinine with Estima Electronically signed by Ordering user: Dronca, Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Mass Rectum [R19.09] <u>Provider Details</u> <u>Provider</u> Dronca, Roxana S,	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa ated GFR [2222487049948 y: Dronca, Roxana S, M.D Roxana S, M.D. 05/06/19 Roxana S, M.D. 5/06/19 - f Bladder Lateral Wall (HCG	Blood, Vend II (HCC) [C67.2 (IC (Completed) on 05/06/19 0940 0940	D-10-CM)] Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect	Status: Complete
Pain Arm Left [M Malignant Neople Creatinine with Estima Electronically signed by Ordering user: Dronca, Authorized by: Dronca, Frequency: Routine 05 Quantity: 1 Diagnoses Pain Rectal [K62.89] Malignant Neoplasm Of Mass Rectum [R19.09] Provider Details Provider	Blood 179.602 (ICD-10-CM)] asm Of Bladder Lateral Wa ated GFR [2222487049948 y: Dronca, Roxana S, M.D Roxana S, M.D. 05/06/19 Roxana S, M.D. 5/06/19 - f Bladder Lateral Wall (HCG	Blood, Vend II (HCC) [C67.2 (IC (Completed) on 05/06/19 0940 0940	D-10-CM)] Ordering provider: Dronca, Roxana S, M.D. Ordering mode: Standard Class: Lab Collect	Status: Complete



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

ID	Туре	Source	C-U-LILE	
-	Blood	Blood, Ven	Collected By	
-				
Indications				
Malignar	ctal [K62.89 (ICD-10-CM)] ht Neoplasm Of Bladder Lateral ectum [R19.09 (ICD-10-CM)]	Wall (HCC) [C67.2 (IC	D-10-CM)]	
edures		_		
lexible Sigmo	idoscopy [2222487049941] (Co	ompleted)		
Ordering user: Authorized by: Frequency: Roi Quantity: 1 Diagnoses Pain Rectal [K6 Malignant Neop	blasm Of Bladder Lateral Wall (H	19 0940	Ordering provider: Dronca, Roxana S, M. Ordering mode: Standard Class: Clinic Performed	Status: Complete D.
viass Rectum				
Vass Rectum [Provider De				
Provider De Provider	tails		NPI	
Provider De Provider			NPI 1982657052	
Provider De Provider	xana S, M.D.			
Provider De Provider Dronca, Ro	xana S, M.D.			
Provider De Provider Dronca, Ro Questionna Question Region	xana S, M.D. ire		1982657052	
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr	atails xana S, M.D. Ire reference		1982657052 Answer	
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for	atails xana S, M.D. Ire reference		1982657052 Answer Florida Region Moderate Sedation Other	
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for Other:	rtails xana S, M.D. ire reference procedure:		1982657052 Answer Florida Region Moderate Sedation Other bladder tumor with possible rectal mass	3
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for Other: Patient curr	itails xana S, M.D. ire reference procedure: ently taking antiplatelet or antico		1982657052 Answer Florida Region Moderate Sedation Other bladder tumor with possible rectal mass No	3
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for Other: Patient curr Place perip	itails xana S, M.D. ire reference procedure: ently taking antiplatelet or antico heral IV if no vascular access av		1982657052 Answer Florida Region Moderate Sedation Other bladder tumor with possible rectal mass No Yes	3
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for Other: Patient curr	itails xana S, M.D. ire reference procedure: ently taking antiplatelet or antico heral IV if no vascular access av		1982657052 Answer Florida Region Moderate Sedation Other bladder tumor with possible rectal mass No	8
Provider De Provider Dronca, Ro Questionna Question Region Sedation Pr Reason for Other: Patient curr Place perip	itails xana S, M.D. ire reference procedure: ently taking antiplatelet or antico heral IV if no vascular access av		1982657052 Answer Florida Region Moderate Sedation Other bladder tumor with possible rectal mass No Yes	3

Vitals



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

/ital Signs - Last Re	corded			Most recent update: 5/6/20	019 8:05 AM by Ra Amanda
BP 107/72 (BP Location: Right arm, Patient Position: Sitting, Cuff Size: Large)	Pulse 106	Temp 37.1 °C (Oral)	Ht 180.3 cm	Wt 81 kg	
SpO2 98%	BMI 24.90 kg/m ²				
ication List					
Medication List					
Active at the End Ioratadine (CL Discontinued Instructions: 7	of Visit ARITIN) 10 mg tab by: Bowles, Desiree		Discontinued on: Entered on: 5/6/2	5/22/2019	
	010010				
	ononitrate (IMDUR)) 30 mg 24 hr tablet			
isosorbide mo			Entered on: 5/6/2	2019	
isosorbide mo Instructions: T Entered by: R	ononitrate (IMDUR) ake 30 mg by mout ay, Amanda C			210	
isosorbide mo Instructions: T Entered by: R multivit with n Instructions: C	ononitrate (IMDUR) ake 30 mg by mout ay, Amanda C	h daily.		chewable	
isosorbide mo Instructions: T Entered by: R multivit with m Instructions: C Entered by: R omeprazole (F	ononitrate (IMDUR) Take 30 mg by mout ay, Amanda C nin-folic acid (MEN Chew 200 mg daily. ay, Amanda C PriLOSEC) 40 mg D	h daily. I'S MULTIVITAMIN GUMMIE DR capsule	S) 200 mcg tablet, Entered on: 5/6/2	chewable 2019	
isosorbide mo Instructions: T Entered by: R <u>multivit with m</u> Instructions: C Entered by: R <u>omeprazole (F</u> Discontinued Instructions: T	ake 30 mg by mout ay, Amanda C nin-folic acid (MEN Chew 200 mg daily. ay, Amanda C PriLOSEC) 40 mg D by: Bowles, Desiree Take 40 mg by mout ay, Amanda C	h daily. I'S MULTIVITAMIN GUMMIE DR capsule	S) 200 mcg tablet,	chewable 2019 5/22/2019	
isosorbide mo Instructions: T Entered by: R <u>multivit with m</u> Instructions: C Entered by: R <u>omeprazole (F</u> Discontinued Instructions: T Entered by: R End date: 5/23	ake 30 mg by mout ay, Amanda C nin-folic acid (MEN Chew 200 mg daily. ay, Amanda C PriLOSEC) 40 mg D by: Bowles, Desiree Take 40 mg by mout ay, Amanda C	h daily. I'S MULTIVITAMIN GUMMIE DR capsule e D, R.N. h 2 (two) times a day.	S) 200 mcg tablet, Entered on: 5/6/2 Discontinued on:	chewable 2019 5/22/2019	
isosorbide mo Instructions: T Entered by: R multivit with m Instructions: C Entered by: R omeprazole (F Discontinued Instructions: T Entered by: R End date: 5/2 finasteride (PI Instructions: T	ononitrate (IMDUR) Take 30 mg by mout ay, Amanda C nin-folic acid (MEN Chew 200 mg daily. ay, Amanda C PriLOSEC) 40 mg D by: Bowles, Desiree Take 40 mg by mout ay, Amanda C 2/2019	h daily. I'S MULTIVITAMIN GUMMIE DR capsule D, R.N. h 2 (two) times a day.	S) 200 mcg tablet, Entered on: 5/6/2 Discontinued on:	chewable 2019 5/22/2019 2019	
isosorbide mo Instructions: T Entered by: R multivit with m Instructions: C Entered by: R omeprazole (F Discontinued Instructions: T Entered by: R End date: 5/2: finasteride (PI Instructions: T Entered by: R	ake 30 mg by mout ay, Amanda C nin-folic acid (MEN Chew 200 mg daily. ay, Amanda C PriLOSEC) 40 mg D by: Bowles, Desiree Take 40 mg by mout ay, Amanda C 2/2019 ROSCAR) 5 mg tab Take 5 mg by mouth ay, Amanda C	h daily. I'S MULTIVITAMIN GUMMIE DR capsule D, R.N. h 2 (two) times a day.	S) 200 mcg tablet, Entered on: 5/6/2 Discontinued on: Entered on: 5/6/2 Entered on: 5/6/2	chewable 2019 5/22/2019 2019 2019	



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Medication List (continued)

Instructions: Chew 500 mg daily.	and the second
Entered by: Ray, Amanda C	Entered on: 5/6/2019
simvastatin (ZOCOR) 20 mg tablet	
Instructions: Take 20 mg by mouth at bedtime.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
Instructions: Take 50% of prep night before by 10 pm	and 50% of prep following morning starting at 0500 and finish before
Instructions: Take 50% of prep night before by 10 pm appointment, as directed.	and 50% of prep following morning starting at 0500 and finish before
polyethylene glycol-electrolytes (GoLYTELY) 236- Instructions: Take 50% of prep night before by 10 pm appointment, as directed. Authorized by: Dronca, Roxana S, M.D. Start date: 5/6/2019	
Instructions: Take 50% of prep night before by 10 pm appointment, as directed. Authorized by: Dronca, Roxana S, M.D.	and 50% of prep following morning starting at 0500 and finish before Ordered on: 5/6/2019
Instructions: Take 50% of prep night before by 10 pm appointment, as directed. Authorized by: Dronca, Roxana S, M.D. Start date: 5/6/2019	and 50% of prep following morning starting at 0500 and finish bef Ordered on: 5/6/2019 End date; 5/7/2019

Flowsheets

	d) Ambulatory Fall Risk Screening	
Row Name	05/06/19 0801	
(Do Not Use; Reti	ed) Fall Risk Scale	
(Do Not Use; Retired) Have you fallen in the last year?	No	
Calculated MAP	The state of the s	
Row Name	05/06/19 0804	
Vital Signs		

Custom Formula Data

Row Name	05/06/19 0804	
Vitals		
Pct Wt Change	0 %	
Height (cm)	180.34 cm	

OTHER

-

MAYO CLINIC

05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

BMI (Calculated)	24.9	
Percent Excess	-103.76 Percent	
Weight Loss		
IBW in Ibs	172	
(Bariatric)		
Weight Change Since Last Visit	80.95 kg	
IBW in kg (Bariatric)	78.02	
Preop BMI (Calculated)	0	
BSA (Calculated - sq m)	2.01 sq meters	
IBW/kg (Calculated) Male	75.3 kg	
IBW/kg (Calculated) FEMALE	70.8 kg	
BMI (Calculated)	24.9	
Percent Excess Weight Loss	-103.76 Percent	
IBW in kg (Bariatric)	78.02 kg	
IBW in Ib (Bariatric)	172 lb	
Weight Change Since Last Visit	80.95 kg	
Weight	81 kg	
Weight	81 kg	
Peds Malnutrition Concatenation	2856A71.000A24.9 A0A0A0A56280386 40	
BMI (Calculated)	24.9 kg/m²	
Measurements		
Total Weight	2222 Percent	
Change Percent	LELE I DIGUN	
Weight Change Since Preop	80.95 kgs	
Initial Excess Weight	-78.02 kgs	
Percent of IBW	3660.6 Percent	
EBW (kg)	2853.79 kg	
EBW (lbs)	2845.25 lbs	
Weight Change Since Preop	80.95 kg	
Initial Excess Weight	-78.02 kg	
Percent of IBW	103.78 Percent	
EBW (kg)	2.93 kg	



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

A still see a second state of		
Anthropometrics % Ideal Body	104 % IBW	
Weight		
Vital Signs		
BMI (Calculated)	24.9 kg/m²	
Height and Weight		
Weight Change (gm)	0	
Weight Change (kg)	0	
Height and Weight		
Weight in (lb) to have BMI = 25	178.9	
Lifestyle Factors		
Exercise Total (kCal/wk)	0 kCal/wk	
Body Composition		
BMI: Desirable <25, High Risk >30	Desirable	
Highest Height/Wei	ghi/BMI	
(Retired)Height Within Last 6 months (cm)	71.000	
(Retired)Weight Within Last 6 Months (kg)	81.1363636363636 3636	
(Retired)BMI Within Last 6 Months	24.9	
Highest weight this encounter (one value per encounter)	5/6/2019	
Current Z Scores		
Weight for Length Z Score	0	
Length for Age Z Score	0	

12/30/2021 3:52 PM EST



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

for Length Z		
Score		
Length for Age Z Score		
BMI for Age Z	2856A71.000A24.9	
Score	A0A0A0A56280386	
	40	
15		
Weight for Length	om Within the Last 6 Months	
Z Score Within	u	
Last 6 Months		
Length for Age Z	0	
Score Within Last		
6 Months		
BMI for Age Z	0	
Score Within Last		
6 Months		
Pediatric Malnutritic		
Peds Nutrition	5/6/2019	
Behind Scenes Date Row		
Date Now		
San Said and		
Relevant Labs and		
Temp (in Celsius)	37.1	
Calculations		
Calculations	500 631	
Predicted	500.631	
Predicted Distance	500.631	
Predicted Distance Calculation		
Predicted Distance Calculation Predicted	500.631 441.864	
Predicted Distance Calculation		
Predicted Distance Calculation Predicted Distance		
Predicted Distance Calculation Predicted Distance Calculation for		
Predicted Distance Calculation Predicted Distance Calculation for Women		
Predicted Distance Calculation Predicted Distance Calculation for		
Predicted Distance Calculation Predicted Distance Calculation for Women		
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals	441.864 05/06/19 0804	
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals BP	441.864 05/06/19 0804 107/72	
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals BP Pulse	441.864 05/06/19 0804 107/72 106	
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals BP Pulse Temp	441.864 05/06/19 0804 107/72	
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals BP Pulse Temp Temp src	441.864 05/06/19 0804 107/72 106 37.1 °C Oral	
Predicted Distance Calculation Predicted Distance Calculation for Women incounter Vitals Row Name Enc Vitals BP Pulse Temp Temp src SpO2	441.864 05/06/19 0804 107/72 106 37.1 °C	
Predicted Distance Calculation Predicted Distance Calculation for Women ncounter Vitals Row Name Enc Vitals BP Pulse Temp Temp src	441.864 05/06/19 0804 107/72 106 37.1 °C Oral	

Vital Signs

Height

180.3 cm



05/06/2019 - Comprehensive Visit in Division of Hematology and Medical Oncology in Jacksonville, Florida (continued)

Patient Position	Sitting
OTHER	
Cuff Size	Large
Nutrition Assessmer	
Row Name	05/06/19 0804
Anthropometrics	
Weight change since admission	0 kg
Ideal Body Weight (Calculated)	78.2 kg
Adjusted Body Weight	78.9 Kg
ELW	78.2 Kg
Parenteral	
IBW (kg)	78.2 kg
Simple Vitals	
Simple Vitals Row Name	05/06/19 0804
Row Name Height and Weight	05/06/19 0804
Row Name	05/06/19 0804
Row Name Height and Weight Admission	05/06/19 0804
Row Name Height and Weight Admission Weight	05/06/19 0804
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight	05/06/19 0804 81 kg 05/06/19 0804
Row Name Height and Weight Admission Weight Vital Signs Row Name	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight Low Range Vt 6mL/kq Adult Moderate Range Vt 8mL/kq	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg 625.6 mL/kg
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight Low Range Vt 6mL/kq Adult Moderate	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg 625.6 mL/kg
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight Low Range Vt 6mL/kq Adult Moderate Range Vt 8mL/kq Adult High Range	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg 625.6 mL/kg 782 mL/kg
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight Low Range Vt 6mL/kq Adult Moderate Range Vt 8mL/kq Adult High Range Vt 10mL/kg	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg 625.6 mL/kg 782 mL/kg
Row Name Height and Weight Admission Weight Vital Signs Row Name Height and Weight Low Range VI 6mL/kq Adult Moderate Range Vt 8mL/kq Adult High Range Vt 10mL/kg	05/06/19 0804 81 kg 05/06/19 0804 469.2 mL/kg 625.6 mL/kg 782 mL/kg



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida

Medication List

report is for documentation purposes only. The patient sho	uld not follow medication instructions within
accurate instructions regarding medications, the patient sho	ould instead consult their physician or after visit summar
tive at the End of Visit	
Ioratadine (CLARITIN) 10 mg tablet	
Discontinued by: Bowles, Desiree D, R.N.	Discontinued on: 5/22/2019
Instructions: Take 10 mg by mouth 5 (five) times a week. M-F Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
isosorbide mononitrate (IMDUR) 30 mg 24 hr tablet	
Instructions: Take 30 mg by mouth daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
multivit with min-folic acid (MEN'S MULTIVITAMIN GUMMIE:	S) 200 mcg tablet.chewable
Instructions: Chew 200 mg daily.	
Entered by: Ray, Amanda C	Entered on: 5/6/2019
omeprazole (PriLOSEC) 40 mg DR capsule	
Discontinued by: Bowles, Desiree D, R.N.	Discontinued on: 5/22/2019
Instructions: Take 40 mg by mouth 2 (two) times a day.	
Entered by: Ray, Amanda C End date: 5/22/2019	Entered on: 5/6/2019
finasteride (PROSCAR) 5 mg tablet	
Instructions: Take 5 mg by mouth daily,	LA OFFICIAL
Entered by: Ray, Amanda C	Entered on: 5/6/2019
carboxymethyl-gly-poly80-PF (REFRESH OPTIVE MEGA-3, F	PF,) 0.5-1-0.5 % dropperette
Instructions: Administer into both eyes 2 (two) times a day,	Sheet State in
Entered by: Ray, Amanda C	Entered on: 5/6/2019
ascorbic acid, vitamin C, (VITAMIN C) 500 mg chewable tabl	let
Instructions: Chew 500 mg daily.	a to the second s
Entered by: Ray, Amanda C	Entered on: 5/6/2019
simvastatin (ZOCOR) 20 mg tablet	
Instructions: Take 20 mg by mouth at bedtime.	Contract of the second s
Entered by: Ray, Amanda C	Entered on: 5/6/2019
pped in Visit	

Messages



estionnaire Submission		
From Kermit William Coles Patient Questionnaire	To General Questionnaire Submission Pool Submission	Sent 4/30/2019 11:03 AM
Questionnaire: Curren	t Visit Information	
General	~~~~	
Fatigue Night sweats		
 Vision or eyes	~~~~~	
No eye issues		
Ear, nose, and throat	~~~~~	
Sinus congestion		
Cardiovascular or hear		
No heart issues		
Lungs or breathing		
No respiratory issue	S	
~~~~~~~~~~~	~~~~~~~	
Stomach or bowel Abdominal (belly) pa Heartburn	in or cramping	



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Muscle or bone Back pain/stiffness

Skin

Skin rash

Neurologic Light-headedness

Mental health or mood Loud snoring Excessive daytime sleepiness/tiredness

------

~~~~~~~~

~~~~~~~~~~~~~~~~

Bleeding and lymph nodes Bruises/bleeds easily

~~~~~~~~~

Urinary, reproductive, and genital Pain with urination Urgency Erectile dysfunction

Sexual Orientation and Gender Identity

Question: Sexual orientation:



| Answer: Straight (n | ot lesbian or gay) | |
|--|--------------------|---------------------------|
| Question: Gender ide
Answer: Male | entity: | |
| Question: Sex assigr
Answer: Male | ned at birth: | |
| ealth History | | |
| From
Kermit William Coles
History questionnaire si
2019 at 3:20:54 PM
Questionnaire: Health H
Patient: Kermit W. Cole | | Sent
4/18/2019 4:21 PM |
| Cardiac - Heart: | | |
| Question: Heart attack
Response: No Respons
Date: Comments: | se | |
| Question: Atrial fibrillation
Response: No Response
Date: Comments: | | |
| Question: Congestive H
Response: No Respons
Date: Comments: | | |
| Question: Coronary Art
Response: Yes
Date: 02/01/2007 Com | | |
| | | |



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Date: Comments:

Question: High cholesterol Response: Yes Date: 02/01/2007 Comments:

Pulmonary - Lung:

Question: Asthma Response: No Response Date: Comments:

Question: COPD (e.g. emphysema) Response: No Response Date: Comments:

Question: Pneumonia Response: No Response Date: Comments:

Question: Sleep apnea Response: No Response Date: Comments:

Gastrointestinal - stomach and related organs:

Question: Acid reflux (heartburn) Response: Yes Date: 2009 Comments:

Question: Irritable Bowel Syndrome (IBS) Response: No Response Date: Comments:



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Question: Crohn's disease Response: No Response Date: Comments:

Question: Ulcerative colitis Response: No Response Date: Comments:

Question: Pancreatitis Response: No Response Date: Comments:

Question: Colon polyp removed Response: Yes Date: 12/2018 Comments:

Question: Gallbladder problem Response: No Response Date: Comments:

Question: Liver disease Response: No Response Date: Comments:

Endocrinology - diabetes, bone health and thyroid:

Question: Diabetes Response: No Response Date: Comments:

Question: Osteoporosis Response: No Response Date: Comments:

Question: Osteopenia Response: No Response



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Date: Comments:

Question: Hypothyroidism Response: No Response Date: Comments:

Question: Hyperthyroidism Response: No Response Date: Comments:

Question: Thyroid nodules Response: No Response Date: Comments:

Musculoskeletal - bones and muscle:

Question: Rheumatoid Arthritis (RA) Response: No Response Date: Comments:

Question: Fibromyalgia Response: No Response Date: Comments:

Question: Broken/fractured bone Response: No Response Date: Comments:

Neurology:

Question: Concussion Response: No Response Date: Comments:



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Question: Dementia Response: No Response Date: Comments:

Question: Migraine Response: No Response Date: Comments:

Question: Headache Response: No Response Date: Comments:

Question: Stroke Response: No Response Date: Comments:

Question: TIA (mini stroke) Response: No Response Date: Comments:

Question: Seizure disorder Response: No Response Date: Comments:

Cancer:

Question: Breast cancer Response: No Response Date: Comments:

Question: Colon cancer Response: No Response Date: Comments:

Question: Rectal cancer Response: No Response



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Date: Comments:

Question: Leukemia Response: No Response Date: Comments:

Question: Lung cancer Response: No Response Date: Comments:

Question: Lymphoma Response: No Response Date: Comments:

Question: Prostate cancer Response: No Response Date: Comments:

Question: Melanoma skin cancer Response: No Response Date: Comments:

Question: Skin cancer Response: No Response Date: Comments:

Question: Kidney cancer Response: No Response Date: Comments:

Question: Thyroid cancer Response: No Response Date: Comments:

Question: Other cancer Response: Yes Date: 03/2019 Comments: Bladder cancer



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

General Medical History:

Question: Cataracts Response: Yes Date: 11/3/2015 & 02/14/2017 Comments:

Question: Glaucoma Response: No Response Date: Comments:

Question: Macular degeneration Response: No Response Date: Comments:

Question: Eye - Crossed Response: No Response Date: Comments:

Question: Eye - Lazy Response: No Response Date: Comments:

Question: Eczema / dry skin Response: No Response Date: Comments:

Question: Dermatitis Response: No Response Date: Comments:

Question: Psoriasis Response: No Response Date: Comments:

Question: Anxiety Response: No Response



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Date: Comments:

Question: Depression Response: No Response Date: Comments:

Question: Kidney disease Response: No Response Date: Comments:

Question: Kidney stone Response: No Response Date: Comments:

Question: Enlarged prostate (BPH) Response: Yes Date: 2006 Comments:

Question: Blood transfusion Response: No Response Date: Comments:

Question: Clotting disorder Response: No Response Date: Comments:

Question: Anemia Response: No Response Date: Comments:

Question: Tuberculosis (TB) Response: No Response Date: Comments:

Question: HIV Response: No Response Date: Comments:



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Question: Hepatitis B Response: No Response Date: Comments:

Question: Hepatitis C Response: No Response Date: Comments:

Question: Sexually Transmitted Infection Response: No Response Date: Comments:

Question: Anesthetic complications Response: No Response Date: Comments:

Question: Other major health conditions that have required treatment or monitoring. Response: No Response Date: Comments:

Social History:

Question: How would you describe your smoking tobacco use? Response: Former Smoker What kind of smoking tobacco products do you use?: Cigarettes On a typical day when you smoke, how many packs do you use? (20 cigarettes = 1 packs): For how many years have you smoked tobacco?: 42 When did you start smoking tobacco?: 10/1/1965 When did you start smoking tobacco?: 2/1/2007 Question: Do you use smokeless tobacco? Response: Never Used Comments:



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Question: Do you consume alcohol? Response: No

Question: Drug Use Response: No

Question: Sexually Active Response: Not Currently Partners: Female Birth Control / Protection: None Comments:

Surgical History:

Question: Carotid artery Response: No Response Date: Comments:

Question: Sinus surgery Response: No Response Date: Comments:

Question: Thyroid surgery Response: No Response Date: Comments:

Question: Tonsillectomy (tonsils removed) Response: No Response Date: Comments:

Question: Heart bypass Response: No Response Date: Comments:

Question: Heart stent



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Response: No Response Date: Comments:

Question: Heart valve surgery Response: No Response Date: Comments:

Question: Lung surgery Response: No Response Date: Comments:

Question: Appendectomy (appendix removed) Response: Yes Date: 1959 Comments:

Question: Colon or large intestine surgery Response: No Response Date: Comments:

Question: Gallbladder removal Response: No Response Date: Comments:

Question: Weight loss surgery Response: No Response Date: Comments:

Question: Hernia repair Response: No Response Date: Comments:

Question: Splenectomy (spleen removed) Response: No Response Date: Comments:

Question: Abdominal aneurysm repair Response: No Response Date: Comments:



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Question: Organ transplant Response: No Response Date: Comments:

Question: Bladder surgery Response: No Response Date: Comments:

Question: Spine surgery Response: No Response Date: Comments:

Question: Arteries in legs Response: No Response Date: Comments:

Question: Joint replacement - shoulder Response: No Response Date: Comments:

Question: Joint replacement - knee Response: No Response Date: Comments:

Question: Joint replacement - hip Response: No Response Date: Comments:

Question: Vasectomy Response: No Response Date: Comments:

Question: Prostate surgery Response: No Response Date: Comments:

Question: Breast enhancement/implants



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Response: No Response Date: Comments:

Question: Breast, mastectomy Response: No Response Date: Comments:

Question: Other surgery Response: Yes Date: 1963 Comments: Hemorrhoid surgery

Family Medical History:

Family Medical History:

Problem: Coronary artery disease (Heart attack, Coronary stent, Bypass surgery)

Relation: Father Name: Kermit Kirk Coles Comments: Heart attack at 80

Relation: Mother Name: Marjorie Coles Comments: Heart attack at 91

Relation: Maternal Grandfather Name: Rudolph Bader Comments: Heart attack at 50

Problem: Stroke

Relation: Father Name: Kermit Kirk Coles Comments: 84



05/06/2019 - Nurse Only in Mangurian Clinic Registration and Business Services in Jacksonville, Florida (continued)

Messages (continued)

Problem: Diabetes

Relation: Father's Brother Name: Frank Coles Comments: 60

Problem: Asthma

Relation: Paternal Grandfather Name: Kirk Coles Comments: 50

Problem: ADD/ADHD

Relation: Son Name: William Coles Comments: 7

Questionnaires

Legend:

Triggered a BPA Scoring question

Mc Current Visit Information Questionnaire

| Question | 4/30/2019 11:03 AM EST
Filed by Patient |
|------------------------------------|--|
| General | |
| Fatigue | Yes |
| Fever | |
| Weight gain of more than 10 pounds | |
| Weight loss of more than 10 pounds | |
| Loss of appetite | |
| Night sweats | Yes |
| No general issues | |



| Vision or eyes | |
|---------------------------------------|--|
| Sudden loss of vision | |
| Visual problems | |
| Double vision | |
| No eye issues | Yes |
| Ear, nose, and throat | 1. 1. N. |
| Difficulty hearing | |
| Persistent hoarse voice | |
| Sinus congestion | Yes |
| No ENT issues | |
| Cardiovascular or heart | |
| Chest pain, pressure or tightness | |
| Rapid or fluttering heart beats | |
| Swelling in the legs or feet | |
| Shortness of breath when lying flat | |
| Pain in the calf muscles when walking | |
| No heart issues | Yes |
| ungs or breathing | |
| Shortness of breath | |
| Coughing up mucus (phlegm) | |
| Coughing up blood | |
| Dry cough | |
| Wheezing | |
| No respiratory issues | Yes |
| Stomach or bowel | |
| Abdominal (belly) pain or cramping | Yes |
| Difficulty swallowing | |
| Heartburn | Yes |
| Nausea | |
| Vomiting | |



| Diarrhea | |
|--|-----|
| Blood in stool | |
| No GI issues | |
| Muscle or bone | |
| Muscle pain/stiffness | |
| Pain or stiffness in the joints | |
| Joint swelling | |
| Back pain/stiffness | Yes |
| No muscle/bone issues | |
| Skin | |
| Skin rash | Yes |
| Change in mole or skin spot | |
| Breast lump | |
| Nipple discharge | |
| No skin issues | |
| Neurologic | |
| Headache | |
| Blackouts | |
| Loss of consciousness | |
| Seizures | |
| Light-headedness | Yes |
| Numbness or shooting pain in hands, arms, legs or feet | |
| Weakness in arms and/or legs | |
| Slurred speech | |
| Loss of balance or tendency to fall easily | |
| No neurologic issues | |
| Mental health or mood | |
| Change in sexual drive (decreased libido) | |
| Loud snoring | Yes |
| Excessive daytime sleepiness/tiredness | Yes |



| Stop breathing, choking, or gasping while asleep | |
|---|------------------------------|
| Little interest or pleasure in doing things | |
| Feeling down, depressed, or hopeless | |
| Feeling nervous, anxious or on edge | |
| Not being able to stop or control worrying | |
| No mental health issues | |
| Bleeding and lymph nodes | |
| Enlarged lymph nodes | |
| Bruises/bleeds easily | Yes |
| No blood/lymph issues | |
| Urinary, reproductive, and genital | |
| Frequent urination | |
| Pain with urination | Yes |
| Difficulty urinating | |
| Urgency | Yes |
| Incontinence (urine leakage) | |
| Blood in urine | |
| Erectile dysfunction | Yes |
| No urinary/reproductive issues | |
| Sexual Orientation and Gender Identity | |
| Sexual orientation: | Straight (not lesbian or gay |
| Gender identity: | Male |
| Sex assigned at birth: | Male |
| Icome Accident Related Questionnaire | |
| | 5/6/2019 8:53 AM EST - |
| | Filed by Patient |
| Question Is this visit related to a workers' compensation, auto, or third-party liability accident? | Representative |